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ABSTRACT 
 
 Obesity and chronic low-grade inflammation are linked to the development of insulin 
resistance and type 2-diabetes. A component to the response to obesity is the accumulation of 
extracellular matrix (ECM) in adipose tissue in what is known as adipose tissue fibrosis, which 
limits the mechanical flexibility of the ECM and promotes metabolic disease by inhibiting 
metabolic adaptation by altering adipocyte function. Currently, the dynamics of ECM 
reorganization in adipose tissue with obesity and the sources of ECM components are not well 
understood. To address this, we investigated the changes in ECM architecture that occur with 
obesity and weight loss. We also explored the role of adipose tissue macrophages (ATMs) in 
influencing ECM remodeling in adipose tissues. Experiments addressed the organization of 
elastin, a relatively unexplored adipose tissue ECM component, and its response to diet induced 
obesity in mice. Our observations revealed ATM interactions with a dynamic mesh-like elastin 
network that becomes denser in adipose tissue of obese animals. The elastin matrix was found to 
be remodeled by obesity independently of MMP-12 and that an MMP-12 deficiency does not 
influence whole body metabolism. As another major component of adipose tissue ECM, we 
investigated the source of the excessive collagen production in adipose tissue in the context of 
weight gain and weight loss, with the hypothesis that ATM-preadipocyte communication is 
central to ECM production. Preadipocytes (CD31-CD45-Sca1+PDGFRα+) were found to be a 
primary source of fibrillar type I collagen, and that obesity expanded the number of collagen-
expressing cells, but also induced its expression at a per cell level. Investigations into 
mechanisms that activate pro-fibrotic preadipocytes revealed that tissue resident macrophages are 
xii	  	   	  
a major source of TGFβre and that TGFβan signaling is required for induction of collagen I 
production in preadipocytes. We also reveal that unexpectedly, weight loss significantly increases 
fibrotic ECM deposition, and this was associated with persistent adipose tissue metabolic 
dysfunction despite normalization of body weight and fat pad mass. Data suggests collagen I and 
elastin- producing preadipocytes increase in density after weight loss. We conclude that 
preadipocytes are a major source of collagen type I and elasin with both weight gain and weight 
loss. Our results suggest that ATMs are a source of TGFβ and that it is required for activation of 
a collagen I production in preadipocytes. This data provides insights into how physiologic and 
pathophysiologic remodeling differs in adipose tissue and identifies potential nodes for 
intervention to break the link between obesity and disease.    
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Chapter 1 
 
 
Introduction: The Regulation of Adipose Tissue Remodeling 
 
 
Abstract 
 
 
 The ability of adipose tissue to adapt to a changing nutrient environment is critical 
to the maintenance of metabolic control.  Nutrient excess and deficiency alter the shape 
of adipose tissue drastically and trigger many events that are collectively known as 
adipose tissue remodeling. The interest in adipose tissue remodeling has been accelerated 
by the current epidemic of obesity and its associated morbidities including diabetes and 
metabolic syndrome. Excess adipose tissue ECM deposition has recently been recognized 
as a hallmark of obesity associated with metabolic disease.  This chapter summarizes and 
highlights the recent work in this area and provides a framework in which to consider 
how the remodeling events in lean and obese states, with information about the potential 
role adipose tissue macrophages (ATMs) play in this process.  Advancing our 
understanding of the involvement of macrophages in adipose tissue remodeling will 
enhance our understanding of one aspect of the new field of “immunometabolism” which 
connects control systems developed for regulation of immunity with those that control 
This	  chapter	  has	  been	  published:	  Martinez-­‐Santibanez	  G,	  and	  Lumeng	  CN.	  Macrophages	  and	  the	  	  
2	  	   	  
metabolism.  It also provides insights into how physiologic and pathophysiologic 
remodeling differs in adipose tissue and identifies potential nodes for intervention to 
break the link between obesity and disease.   
 
Introduction 
As the body’s main site of nutrient storage, adipose tissue must be able to quickly 
respond to both nutrient deprivation and excess. These responses place demands on 
adipose tissue to be able to dynamically react to the changing nutrient environment.  This 
dynamic alteration of adipose tissue structure, size, and shape is generally referred to as 
adipose tissue remodeling.  While the regulation of energy uptake and fatty acid release 
by adipocytes is well understood at the molecular and cellular level, a supporting network 
of non-adipocyte cells and extracellular components provides an additional layer of 
control over adipocyte function.  These stromal components include immune cells such 
as macrophages, and non-immune cells like vascular endothelial cells and preadipocytes, 
all of which participate in the regulation of adipocyte function.  Understanding the 
properties of this complex supporting network in adipose tissue has become increasingly 
important due to the current obesity epidemic.  Being overweight or obese can result in 
adipose tissue dysfunction, which contributes to metabolic disease by ultimately shifting 
lipid accumulation to non-adipose tissues (e.g. liver and muscle) (217).  This introduction 
focuses primarily on current understandings of the changes in the ECM that occur with 
obesity that contribute to adipocyte function and dysfunction.  
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Defining adipose tissue remodeling 
 
 The concept of adipose tissue remodeling has been applied broadly to encompass 
the range of events that occur to adipose tissue depots in response to nutrient excess or 
deficiency (112, 201, 202)  (Figure 1-1). Remodeling has been used to describe the 
changes in the cellular composition of the adipose tissue stromal cell network in response 
to both adipose tissue expansion and contraction (202, 203).  Others use this term to 
describe the deposition and breakdown of the non-cellular components of adipose tissue 
that contribute to its structure (e.g. the ECM).  To add to this complexity, adipose tissue 
remodeling has been used to describe the changes in adipose tissue structure in both 
physiological/adaptive settings (e.g. embryonic development, puberty, pregnancy, and 
weight loss (67, 106, 156) as well as changes that occur in pathologic settings (e.g. 
obesity or lipodystrophy (201). 
 We broadly define adipose tissue remodeling as the process by which adipose tissue 
changes shape, size, structure, and composition.  This definition includes the stromal and 
ECM changes referenced above, but also encompasses changes in adipocyte size 
(hypertrophy) and the generation of new adipocytes (hyperplasia/adipogenesis).  It also 
includes alterations in adipose tissue angiogenesis that are important regulators of 
nutrient delivery to fat.  Like most complex systems, these events are all highly 
interdependent.  For example, adipogenesis requires ECM degradation (41), angiogenesis 
(56), and the coordination with signals from ATMs (114). 
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Adipocyte maintenance 
 
Two primary mechanisms contribute to the volumetric expansion of adipose 
tissue.  With an acute excess of nutrient intake, enlargement in the size of individual 
adipocytes (hypertrophy) can occur rapidly due to an increase in lipid (triglyceride) 
stores.  Alternatively, adipose tissue can expand by generating new adipocytes 
(hyperplasia) from a preadipocyte precursor population.  The relative balance between 
these processes appears to be highly dependent on the location of the fat pad in an 
organism.  For example, in rats, visceral fat depots appear to expand primarily by 
hypertrophy, while subcutaneous fat depots expanded primarily via hyperplasia (50).  
Recent lineage tracking studies in mice show that visceral fat develops primarily post-
natally which contrasts with subcutaneous adipose tissue (227). With diet-induced 
obesity, adipogenesis is initiated after four weeks of high calorie diet while subcutaneous 
adipose tissue expands by hypertrophy primarily for up to 12 weeks. 
The mechanisms utilized in human adipose tissue expansion in obesity are not 
fully delineated, and patterns of fat deposition and expansion vary substantially between 
individuals.  This variation in adipose tissue distribution likely drives the differences in 
metabolic disease risk seen between individuals with similar degrees of adiposity.  A 
consistent observation in obese individuals is that metabolic dysfunction is associated 
with large adipocytes and the impaired ability to generate new adipocytes (66, 85).  This 
may be due to altered gene expression in large adipocytes that overexpress inflammatory 
genes (89).  Others have suggested that it is an over abundance of small adipocytes that 
can no longer hypertrophy that is associated with a more deleterious metabolic phenotype 
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(136, 137).   In both settings, the net effect is the same; the ability of adipose tissue to 
function as an efficient storage vehicle is impaired, forcing other peripheral tissues to 
compensate by inappropriately accumulating lipid.   
Animal studies to support the benefits of efficient adipose tissue expansion came 
from a remarkable study by the Scherer lab (99).  Mice were generated that lacked leptin 
and overexpressed adiponectin.  In this setting, the mice were severely obese but 
surprisingly had normal metabolic profiles with normal glucose tolerance and protection 
from fatty liver disease.  The robust capacity of the adipose tissue to act as a nutrient sink 
in these animals was shown to occur even with high calorie diets as the mice weighed as 
much as 135g without evidence of abnormal metabolism.  The protective phenotype in 
this setting was associated with preferential partitioning of storage to subcutaneous fat 
depots, expansion of small adipocytes, and the absence of inflammatory cells (ATMs in 
particular).  Thus, if adipose tissue is able to retain properties that promote efficient fat 
expansion in the face of tremendous nutrient load, metabolic health may be maintained in 
with severe obesity.  Such mechanisms may be at play in individuals who display a 
metabolically healthy obese phenotype (13, 23) 
Understanding the interaction between adipocyte hypertrophy and hyperplasia 
requires an understanding of the dynamics and kinetics of adipocyte turnover – an issue 
that has remained poorly understood until recently in humans.  By taking advantage of 
worldwide exposure to 14Carbon with aboveground nuclear testing in the 1950’s, 
Spalding and colleagues estimated the turnover rate of adipocyte to be approximately 
10% per year regardless of BMI status (196).  The rate of lipid turnover within adipose 
tissue appears to be an important variable as well.   Metabolic disease is associated with 
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decreased rates of lipid storage and release from adipocytes (10).   In addition, there 
exists a wide variation in the balance between hyperplasia and hypertrophy in 
subcutaneous fat depots between individuals independent of adipocyte turnover rates (9).  
The contribution of these factors to metabolic disease is supported by the observation that 
women with a predominant adipocyte hypertrophy profile had worse insulin resistance 
than those with a hypertrophic profile (196). There remain many important unanswered 
questions in this field regarding whether the number of adipocytes in the adult reach a 
finite number during obesity, or if there is continuous turnover of adipocyte precursor 
populations. 
Much of what we know about the molecular regulation of adipogenesis is largely 
derived from in vitro cells lines that exhibit adipogenic capacity (184).  Over the past 
several years, there has been significant progress made in identifying specific populations 
of preadipocytes in vivo and understanding their differentiation capacity.  This is a fast 
developing field that overlaps with the efforts to identify multi-potent adipose tissue stem 
cells with differentiation capacity beyond adipocytes (e.g. chondrocytes and osteocytes) 
(31). Previous studies have relied on combinations of mouse genetic lineage tracing, 
surface marker analysis by flow cytometry, and adoptive transfer to validate adipogenic 
capacity (17, 114).  
Using these techniques, a number of putative committed preadipocyte populations 
have been identified.  Using platelet derived growth factor receptor alpha (PDGFRα) 
reporter mice, Lee et al identified a Sca-1+ CD34+ PDGFRα+ population in adipose tissue 
with the potential to differentiate into either white or brown adipocytes in the setting of 
lipolysis-stimulated adipose tissue remodeling in mice (115).  These observations overlap 
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with Berry et al who report a population of PDGFRα+ preadipocytes that also co-express 
CD24 (17, 183).  Commitment to the adipocyte lineage is associated with down 
regulation of CD24 expression.  Lineage tracing experiments with adipogenic 
transcription factors PPARγ and Zfp493 identifies committed preadipocytes tightly 
associated and possibly coinciding with endothelial cells in adipose tissue (64, 210, 211, 
213).  How these endothelial derived precursors map onto the PDGFRα+ precursors has 
yet to be fully detailed.   
 
Angiogenesis and hypoxia 
 
 The expansion of fat is directly related to access to nutrients and gas exchange from 
the blood supply. All adipose tissue depots are highly vascularized.  An extensive 
capillary network is formed in association with adipocytes (35, 152).  In adipose tissue 
expansion, blood vessel development (angiogenesis) precedes adipogenesis and 
establishes the architecture of visceral fat pads in mice (67, 70).   In humans, angiogenic 
potential is not equal in all white adipose tissue depots.  Explant experiments show a 
higher angiogenic capacity of subcutaneous adipose tissue compared to visceral adipose 
tissue samples (61).  Adipose tissue from obese patients showed a lower angiogenic 
capacity that was associated with insulin resistance (197). This is consistent with the 
observation that obesity decreases the density of capillaries in adipose tissue while 
increasing the size of larger vessels.  
Angiogenesis in adipose tissue is regulated by a wide range of pro- and anti-
angiogenic factors.  Pro-angiogenic factors are secreted by adipocytes, preadipocytes, 
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endothelial cells, and inflammatory cells (179).  Growing adipocytes produce pro-
angiogenic factors that include VEGF, FGF-2, HGF, IGF, TNFα and TGFβ (116).  
Adipokines can also positively and negatively regulate angiogenesis. Leptin has the 
potential to activate a pro-angiogenic program (225).  Adiponectin has been suggested to 
have both pro- and anti- angiogenic effects (181, 224). On balance, evidence primarily 
suggests that Adiponectin is sufficient to promote angiogenesis in overexpression models 
(99, 109).    
Adipogenesis is dependent on appropriate angiogenesis, as it has been shown that 
the modulation of vascular supply can regulate adipose tissue mass (185).  VEGF is 
referred to as a master regulator of angiogenesis and is essential for the activation of the 
growth of new blood vessels (168).  Blockade of VEGF receptor signaling along with 
high calorie diets can block adipose tissue angiogenesis and inhibit fat expansion (207).  
Conversely, overexpression of VEGF in adipose tissue increases blood vessel density and 
protects against diet-induced obesity, potentially by blunting hypoxia signals and 
increasing thermogenesis (56).  
 A potent drive for new blood vessel formation is tissue hypoxia, and there is 
evidence from several studies that obesity generates a hypoxic environment in adipose 
tissue (77, 239).  This hypoxia may be a means by which adipocyte hypertrophy 
generates a pro-inflammatory response (171, 172, 178).   In vitro, adipocytes and SVF 
cells respond to a hypoxic environment with an induction of inflammatory cytokine 
production (58, 158).  While this hypoxic environment may relate to decreased diffusion 
of oxygen in hypertrophic adipocytes, there is evidence that obesity also impairs blood 
flow to adipose tissue.  Total blood flow into white adipose tissue is not increased in 
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obese patients despite tissue enlargement (222).   In addition, obese patients have been 
shown to have a blunted post-prandial increase in blood flow to adipose tissue (94).  
 An important outstanding issue in the discussion of adipose tissue hypoxia and 
obesity is the measurement methods employed.  The reported partial pressures of oxygen 
(44-55 mmHg (171, 172)) are actually quite high compared to many other tissues (e.g. 
muscle and brain pO2 are around 30mmHg (30)). Therefore, it is likely more accurate that 
there is a relative degree of tissue hypoxia occurring in adipose tissue with obesity.  More 
intriguingly, this suggests the possibility that many non-hypoxic mechanisms have yet to 
be discovered that may be driving many of the angiogenic signals in expanding fat if this 
is the case.   
 While many molecular pathways are activated in response to hypoxia, activation of 
hypoxia-inducible factor-1α (HIF-1α) is a key event that is triggered in obese adipose 
tissue (72).  The role of this activation may have less to do with angiogenesis and more to 
do with regulation of the ECM.  Transgenic overexpression of a constitutively active 
form HIF-1α in adipose tissue did not increase angiogenesis (65). Instead, overexpression 
of HIF-1α induced the expression of multiple ECM components and ECM remodeling 
genes including Col1a1, Col3a1, Eln, Lox, Timp1, and increased tissue inflammation.  
Overall, while hypoxia may be a drive for new vessel formation in some conditions, in 
obesity it may primarily serve as a pro-fibrotic and pro-inflammatory signal. 
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Extracellular matrix composition in adipose tissue 
 
 The ECM is a crucial component of adipose tissue that is necessary for maintaining 
cellular and structural integrity. The ECM is also a source for mechanical signals for 
proper growth and differentiation, and provides a medium for cell-ECM and cell-cell 
crosstalk. This communication permits cells to sense and adapt to their changing 
microenvironment. The generation, maintenance and degradation of adipose tissue ECM 
is regulated by numerous cellular components in adipose tissue, including inflammatory 
cells and adipocytes themselves (Figure 1-2).  
The ECM surrounding adipocytes is composed of numerous protein and 
carbohydrate components that include collagens, laminins, fibronectin, proteoglycans, 
and many more (62, 190). Adipocytes develop in the context of a dense ECM matrix that 
significantly changes throughout development and during adipogenesis.  Preadipocyte 
differentiation triggers a dynamic deposition of all collagen types followed by later 
degradation of the ECM during the later stages of differentiation (141, 147).  ECM 
scaffolding in fat is also composed of the basement membrane, which contains a large 
complex of Collagen IV, Collagen VIII, as well as heparan sulfate proteoglycans 
laminins (176, 190).  To bind with the ECM, adipocytes will crosslink their own 
Collagen VI to the basement membrane. This may be achieved through protein cross-
linking via the enzymes Lysyl Oxidase and Transglutaminase, which may modulate 
adipogenesis  (52, 81). 
Adipose tissue ECM is composed of both fibrillar (Col I, III) and non-fibrillar 
(Col IV, VI, VIII) collagens. A unique aspect of adipose tissue is that it contains the 
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highest concentration of Collagen Type VI compared to other tissues (97, 170).  Collagen 
VI has been shown to correlate with body mass index and be up regulated in adipose 
tissue with obesity and short term overfeeding (170).  ATMs are tightly associated with 
Collagen VI-rich areas in fat where they demonstrate an alternative-activated phenotype 
(198).  The importance of Collagen VI in controlling adipocyte shape with over nutrition 
was shown in studies of mice deficient for Collagen VI, who demonstrate an exaggerated 
capacity for adipocyte hypertrophy (97). Collagen VI cleavage products can also generate 
signaling molecules which can promote fibrosis via increasing the recruitment of 
macrophages and activating TGFβ signaling (169).  It is also clear that other collagens 
besides Collagen VI are important in adipose tissue remodeling.  In obese children, 
increased collagen content in adipose tissue correlated with decreased fat cells size and 
body mass index that was not related to Collagen VI (206).  
Beyond the components that make up the ECM, a variety of other control 
mechanisms tie ECM signals to cellular function.  One example of this in adipose tissue 
is SPARC (secreted protein acidic and rich in cysteine; osteonectin) and its associated 
complex. The SPARC complex has been implicated in regulating cell-matrix interactions, 
angiogenesis, activation of matrix metalloproteinases (MMPs), and modification of 
cytokines and growth factors (27).  SPARC binds to numerous proteins including 
thrombospondins 1 and 2, osteopontin, fibrillar collagens, and tenascins C and X, and 
may therefore contribute to the organization of the ECM in fat and its interaction with 
adipocytes (187).  
SPARC is induced with obesity and with adipogenesis (33).  It is expressed higher 
in subcutaneous adipose tissue compared to visceral adipose tissue and correlates with 
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BMI and waist circumference (113).  Sparc-null mice have larger body weights and 
larger white adipose depots on normal and high fat diet challenge (26, 150).  These 
observations correlated with decreased adipose tissue collagen content in the Sparc-null 
mice. The mechanism behind these effects may relate to the close relationship between 
ECM signals and adipogenesis, as even bone marrow derived cells from SPARC-null 
mice had increased adipogenic potential.  This may also relate to the capacity for SPARC 
to directly inhibit adipogenesis via an enhancement of β-catenin signaling (151). 
 
Extracellular matrix maintenance and turnover in obesity 
 
Both adipose tissue expansion and reduction require an extensive reorganization 
of the ECM to permit the changes in shape.  Gene expression analysis supports the idea 
that ECM maintenance is dynamically regulated over the lifetime of an adipocyte (127, 
157).  During the early stages of adipocyte hypertrophy and the development of obesity, 
there is an increase in ECM deposition (147).  As tissue hypertrophy continues, the 
deposition and maturation of ECM components accumulates and is dynamically 
modified.  Extracellular proteolytic enzymes primarily control ECM degradation.  There 
are many families of proteins that enact this activity, some of which include the MMPs, 
ADAMs/ADAMTs (a-desintegrin and metalloproteinase with thrombospondin motifs), 
urokinase type (u-PAs), tissue type plasminogen activators (t-PA) and plasminogen 
activator inhibitors (PAIs).  
A better understood family of ECM degrading systems in adipose tissue is the 
20+ member, zinc-dependent family of matrix metalloproteinases (MMPs) (146).  MMPs 
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are loosely classified according to their substrate specificity, although there is substantial 
redundancy in their activities (223).  Still, it is generally believed that the complete MMP 
collection is able to degrade most, if not all, of the ECM components in tissues. MMPs 
activity can be regulated by a family of endogenous inhibitors, called the Tissue 
Inhibitors of Metalloproteinases (TIMPs) which have their own range of specificity of 
action towards MMPs (220).  Beyond their ability to cleave ECM components, MMPs 
can also target various signaling molecules, growth factors, and cell adhesion molecules 
with likely effects on adipose tissue function (155).  For example, MMP-12 can truncate 
CXC-type chemokines that are important in macrophage recruitment and mobility (47). 
MMP can activate pro-IL1β, TNFα, and plasminogen as well as activate other MMPs 
(69, 188). MMPs can also release and activate TGFβ within the ECM (129, 240). Almost 
all of these pathways have been implicated in adipocyte function and adipogenesis, which 
implies the range of activity MMPs play in adipose tissue remodeling.  
Transcriptional profiling has shown significant changes in the expression of 
MMPs and TIMPs in adipose tissue from diet-induced obesity models and genetic models 
of obesity (34, 132).   The predominant source of MMPs and TIMPs are unclear, however 
adipocytes can stimulate MMP activation in response to macrophage derived 
inflammatory signals (157).  While many MMPs and TIMPs are induced with obesity, 
some are down regulated or unchanged.  
 Several studies have shown that MMPs are required for proper adipose tissue 
expansion. Pharmacological inhibition of MMP activity has been shown to suppress 
adipocyte differentiation in vitro (169).  In vivo administration of a broad-spectrum MMP 
inhibitor was able to significantly restrict the growth of both subcutaneous and visceral 
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adipose tissue of animals fed high fat diets (48, 119). In this setting, MMP inhibition led 
to the accumulation of collagen-dense matrix surrounding adipocytes and smaller fat 
depots, demonstrating the importance of MMPs in adipose tissue ECM degradation and 
control of adipose tissue shape.  
Specific inhibition of MMP-2, an enzyme that can degrade Collagen IV and the 
basement membrane, can promote differentiation of pre-adipocyte cell lines in vitro 
(218).  However, in vivo inhibition of MMP-2 in mice fed a high fat diet decreased body 
weight gain without an impact on fat pad weight. MMP-2 inhibition reduced adipocyte 
size and blood vessel density suggesting that MMP-2 may more important in the 
regulation of adipocyte hypertrophy and angiogenesis. Consistent with this, treatment of 
obese mice with the MMP-2 inhibitor had a primary influence on blood vessel size, 
suggesting a role for MMP-2 in maintaining angiogenesis. Similar results were seen with 
MMP-2 deficient mice which have attenuated weight gain and smaller fat pads when fed 
a high fat diet (219). The differences between in vitro and in vivo results in this study 
further advocate the need to understand adipose ECM in the context of the entire stromal 
network.  
 Another striking example of the limitations of in vitro analysis of adipose tissue 
ECM come from studies examining the role of the membrane type MMP-14 (MT1-
MMP) (41, 42).  Mmp14 null mice exhibit decreased adipose tissue mass.  When 
preadipocytes were cultured on standard tissue culture plates, adipogenesis was observed 
to proceed undisturbed.  However, when placed in a dense three dimensional collagen 
matrix, preadipocytes from Mmp14 null mice were unable to grow and differentiate.  This 
ability was restored when the matrix was of a lower density and demonstrated the 
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requirement of adipocyte derived MMP-14 to cleave and loosen their pericellular ECM 
and permit adipocyte expansion.  
 In terms of TIMPs in adipose tissue, the role of TIMP-1 and its role in regulating 
MMP activity has been the most studied to date. Transgenic over-expression of TIMP-1 
increases adipocyte differentiation and lipid storage in mammary gland adipose tissue (4).  
However, overexpression of human TIMP-1 in 3T3-F442A adipocytes and in transgenic 
mice had little effects on adipocyte differentiation, adipose tissue expansion, or body 
weights (49).  Attenuating TIMP-1 activity with a neutralizing antibody enhanced 3T3-
L1 adipocyte differentiation in vitro and also lead to larger adipocytes in vivo (138).   
Moreover, administering recombinant mouse TIMP-1 to mice resulted in early 
development of insulin resistance and higher levels of serum non-esterified fatty acid 
levels along with an increase in hepatic lipid storage.  Timp1 deficient mice have also 
been studied and show lower fat pad weight, smaller adipocytes, and protection from 
diet-induced obesity (118).  Overall, these studies suggest that TIMP-1 contributes to the 
remodeling of adipose tissue by inhibiting certain necessary ECM remodeling activities, 
however the mechanisms of how these events are regulated are unclear.   
The role of TIMP-3 in adipose tissue and adipocyte differentiation has also been 
evaluated. Macrophage-specific TIMP-3 over-expression suggested that TIMP-3 was 
protective towards obesity-induced inflammation and metabolic dysfunction (139).  
Conversely, Timp3 deficient mice showed an increase in both hepatic steatosis and 
adipose tissue inflammation (140). In vitro, TIMP-3 expression is down regulated during 
adipogenesis suggesting that low TIMP-3 expression is required to permit adipocyte 
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hypertrophy (15).  Overall, these results suggest that TIMP-3 may exert another layer of 
control over the extent and timing of ECM degradation in adipose tissue.  
 Collectively, these studies suggest that a tightly controlled balance of ECM 
remodeling enzymes is necessary for proper adipocyte expansion and can influence the 
inflammatory set point of adipose tissue. However, MMPs are often difficult to study 
because they can be regulated at multiple post-transcriptional levels.  Because of the 
multi-step regulatory program of MMPs, future studies focused on how MMP activity is 
regulated in adipose tissue are required.  
 
Adipose tissue fibrosis in obesity and weight loss   
 
 The growing interest in adipose tissue remodeling and the ECM relates to the 
strong correlation between adipose tissue fibrosis and obesity-associated metabolic 
dysfunction (202, 203).  Obesity is associated with an increase in adipose tissue fibrosis, 
a prominent signature in visceral adipose tissue depots that is not regularly observed in 
subcutaneous depots in animals, but may be more prominent in human adipose tissues 
(54, 97). Obesity induces a strong induction of ECM component gene expression, growth 
factors, and enzymes involved in post-translational modifications (20, 74). With obesity, 
it is believed that the imbalance of ECM deposition, ECM degradation, and ECM 
component crosslinking results in accumulation of insoluble fibrotic regions. Beyond 
obesity, fibrosis and expression of certain collagens (e.g. Collagen VI) negatively 
correlate with insulin sensitivity, further implicating fibrosis as a signature of adipose 
tissue dysfunction and poor metabolic health (198). Still, while the majority of findings 
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are consistent in seeing a denser ECM with obesity, the mechanisms by which pathogenic 
fibrosis develops is not understood, and discrete criteria describing at which point the 
fibrotic accumulations result in detrimental influence on adipocyte maintenance and in 
metabolism are still unclear (53).  
 Currently, it is not well understood how modifications of the ECM can affect 
adipose tissue’s ability to store, release, and maintain proper energy balance. Current data 
suggests that adipose fibrosis limits the mechanical flexibility of the ECM, which may 
limit the ability of adipocytes to expand and contract in response to metabolic demand (9, 
10).  In vitro studies suggest that mechanical stress due to an increasingly dense ECM 
inhibits preadipocyte differentiation and hypertrophy (40-42). This limits new adipocyte 
formation and may limit the normal capacity of adipose tissue to store and sequester lipid 
and contributes to the increase in lipid deposition in peripheral non-storage tissues such 
as the liver and muscle. In vitro experiments culturing adipocytes in dense ECM limits 
their sensitivity to insulin, and decreases adiponectin expression and secretion (117). 
Additionally, clinical studies reveal that obese patients have increased ECM density and 
stiffness in subcutaneous adipose tissues (1).  Some reports suggest a possible protective 
role for adipose tissue fibrosis might be to limit adipocyte hypertrophy in visceral adipose 
depots, as smaller adipocyte sizes are associated with a lower inflammatory profile (9, 
10). Overall, the majority of pre-clinical data supports the model that fibrosis promotes 
metabolic dysfunction, however potential benefits to fibrosis have been observed in 
clinical settings.  The differences between the pre-clinical and clinical settings may relate 
to the range of BMI being evaluated, depot being sampled, methods of quantitation of 
fibrosis, and the heterogeneity of human obesity and diabetes status.    
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 The negative effects of ECM on metabolism are highlighted in an animal model 
with impaired ECM deposition. Mice deficient for Collagen VI, an ECM component 
enriched in adipose tissue, were crossed onto a leptin-deficient ob/ob background which 
displays genetic obesity.  The lack of Col6 permitted unrestricted expansion of adipocyte 
size (97). This resulted in an improvement of metabolic parameters and glucose tolerance 
compared to the leptin-deficient controls. This was also associated with fewer crown-like 
structures (CLSs) that represent regions of adipocyte death and inflammation.  These 
findings indicate that increasing the flexibility of the ECM may in fact improve the 
ability of adipocytes to adapt to metabolic demand. This may also indicate that adipocyte 
hypertrophy per se is not sufficient to induce an inflammatory response and that the ECM 
may be a key mediator in translating adipocyte stress. 
 To date, whether or not weight loss resolves adipose tissue fibrosis in humans and 
if it is pathogenic or protective is still under investigation. With weight loss, the ECM 
undergoes significant reorganization that allows for a decrease in adipocyte size (11, 29, 
106). Weight loss can improve a variety of metabolic and inflammatory factors related to 
obesity, however in many cases the risk of cardiovascular disease remains high (237). For 
example, normal weight adults that were obese as children have a 2-3 fold higher risk of 
developing diabetes (177). A striking observation is that the accumulation of ECM 
components appears to persist and even increase in obese patients that have undergone 
weight loss (53, 54). This suggests that resolution of adipose tissue fibrosis may not be 
possible and suggests a potential mechanism for ongoing risk of metabolic disease in 
formerly obese individuals.   
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Fibrosis and mechanical stress 
 
One consequence of fibrotic adipose tissue is an increase in the physical stiffness 
of the microenvironment.  Increased rigidity of the microenvironment can promote self 
renewal of adipocyte progenitors while decreasing their adipogenic capacity (32).  This is 
consistent with the observations that Mmp14 deficient mice have impaired adipocyte 
formation due to the loss of local collagen breakdown (41).  
 A few studies have evaluated the mechanisms by which the mechanical properties 
of the microenvironment modify adipocyte function.  Mechanical stretching of 3T3-L1 
adipocytes inhibits differentiation via ERK-mediated down regulation of PPARγ2 (209). 
Applying a mechanical stress to human preadipocytes by compressive force inhibited 
adipocyte differentiation via COX-2 mediated down regulation of PPARγ2 and C/EBPα 
(78).  These effects were not observed when the compression was done after 
differentiation, suggesting that preadipocytes may be primarily responsive to mechanical 
stress from fibrosis.  
 The Rho/Rho-Kinase (ROCK) signaling pathway plays an important role in the 
mechanotransduction of stress, which converts physical stimuli from the 
microenvironment into biochemical signals.  ROCK is activated in adipose tissue of 
obese Zucker rats, and ROCK activation correlates with the development of glucose 
intolerance via phosphorylation of insulin receptor substrate-1 (IRS-1) (92).  ROCK also 
induces the expression of inflammatory cytokines MCP-1 and TNFα (73, 148). Inhibition 
of ROCK activity by overexpression of an adipocyte-specific dominant-negative RhoA 
attenuated adipocyte hypertrophy, weight gain, and macrophage recruitment to adipose 
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tissues (68).  ROCK inhibition also improved glucose metabolism in mice after high fat 
diet challenge.  Hypertrophy of 3T3-L1 adipocytes was found to correlate with increased 
Rho-Kinase activity and expression of MCP-1 and TNFα. Together, these data may 
demonstrate the importance of adipocyte mechanical sensing in metabolic and 
inflammatory control.  
 
Changes in macrophage populations with obesity 
 
ATMs are the dominant leukocyte population in adipose tissue in both lean and 
obese states.  Both human and mouse ATMs can be subdivided into two general groups 
based on functional observations, however additional studies suggest this model is overly 
simplistic (122, 228). More recent studies however, have described an additional distinct 
ATM subtype associated with obesity, termed the “metabolically active” or MMe subtype 
(107). The resident ATM population has properties that overlap with alternatively 
activated macrophages (M2) and is associated with suppression of the immune response 
and with ECM remodeling.  Resident ATMs are found in all adipose tissue depots and are 
the dominant population in lean states.  A subtype of CD11c+ ATMs are induced with 
obesity and are associated with tissue damage, pro-inflammatory signaling, and the 
generation of TH1 cytokines such as TNFαwhich is a common hallmark of classically 
activated macrophages (M1).  The functions and roles of MMe macrophages in ECM 
remodeling, while being associated with metabolic dysfunction, have not yet been fully 
explored and remains a promising research avenue.  
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Which ATM population contributes more to adipose tissue ECM deposition and 
to pathogenic fibrosis is unclear.  Some studies have attributed remodeling capacity more 
to the CD11c+ M1 ATM subset than the resident ATM subset (25, 192).  This largely due 
to the association between CD11c+ ATM accumulation and adipose tissue fibrosis in 
obese mice.  These observations are not surprising given that the M1/M2 paradigm is an 
in vitro oversimplification and in vivo tissue macrophage likely assume activity along a 
broad spectrum.  The position of ATMs in direct contact with adipocytes, vascular 
endothelial cells, preadipocytes, and the ECM leave them poised to integrate signals from 
a myriad of inputs and alter the behavior of the remodeling environment  (Figure 1-3).  It 
is becoming clear that ATM plasticity is a result of the diverse environment of adipose 
tissue.   
Developmental remodeling of adipose tissue appears to be crucially controlled by 
resident ATMs (67).  Depleting macrophages during development with clodronate 
liposomes inhibited adipogenesis by perturbing angiogenesis in the developing fat pad.  
In post-natal development, ATMs are concentrated in the tips of growing visceral fat pads 
where they may be contributing to ongoing angiogenesis and adipocyte formation by 
regulating VEGF signaling (35, 204).   
In adult animals, resident M2 ATMs provide critical signals that support 
adipogenesis in many types of adipose tissue remodeling.  Lee et al recently identified an 
adipogenic niche that was formed in during prolonged lipolysis (114).  This model of 
studying reorganizations via lipolysis generated CLS due to the death of white adipocytes 
that were enriched in resident M2 ATMs.  This new structure also appears to be critical to 
the generation of new adipocytes, as the ATMs provide signals that trigger preadipocyte 
22	  	   	  
proliferation and new adipogenic foci.  Osteopontin was identified as a signal emanating 
from the M2 ATMs and sensed by the preadipocytes as a migratory and stimulatory 
signal. Osteopontin deficient mice failed to form these regenerative adipogenic foci.   
An important contribution of this paper by Lee et al is the comparison between 
macrophage activation paradigms between several models of induced adipose tissue 
“remodeling.” These included physical disruption, diet induced obesity, and neogenesis 
of adipose tissue in a matrigel plug.  All of these conditions led to the formation of 
similar adipogenic foci, however the macrophage activation profiles differed substantially 
between these conditions.  This suggests a plasticity of ATM function depending on the 
triggers for adipose tissue remodeling and the importance of the local tissue 
microenvironment in generating a macrophage response.   
 A hallmark of obese adipose tissue is the presence of CLS that develop around 
necrotic adipocytes (43, 62).  CLS density is associated with insulin resistance and a pro-
inflammatory environment in adipose tissue (18, 145, 198).  The formation of CLS is 
presumably due to excessive adipocyte hypertrophy and subsequent stress leading to a 
pattern of cell death that resembles necrosis or pyroptosis – a caspase-dependent type of 
programmed cell death.    
 The primary component of CLS are lipid-laden macrophages, however multiple 
leukocytes have been observed to be concentrated there as well, including lymphocytes, 
eosinophils, and mast cells (6, 234).  CLS are enriched for CD11c+ M1-like ATMs which 
take up lipids and cellular debris and generate pro-inflammatory cytokines.  The function 
of ATMs in this context may be to process and prevent lipid release out of adipose tissue.  
Increasing macrophage lipid storage by overexpression of diacylglycerol acyltransferase 
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1 (DGAT1) results in reduced adipose tissue inflammation and an improved metabolic 
profile in obese mice (104).  In addition, this accumulation of M1 ATMs in CLS is 
primarily dependent upon the influx of monocytes from the circulation in response to 
chemotactic signals in adipose tissue (123, 153, 161). 
 
Macrophage regulation of ECM deposition and degradation 
 
 CLS are also associated with dense ECM deposition (43). The localization of M1 
ATMs to these areas suggests that M1 ATMs promote a local pro-fibrotic environment.  
The cells in adipose tissue involved in the deposition of ECM have not been clearly 
delineated.  In many other pro-fibrotic settings, fibroblasts are a major contributor to the 
promotion of ECM accumulation.  In response to pro-inflammatory damage signals and 
growth factors such as TGFβ , fibroblasts can be converted into pro-fibrotic 
myofibroblasts that express Collagen I and smooth muscle actin (α-SMA) (102).  In 
adipose tissue, fibroblasts are abundant and are similar in morphology with adipocyte 
precursors.   
 Evidence suggests a coupling between macrophage pro-inflammatory signals and 
the generation of myofibroblasts in obese adipose tissue.  Pro-inflammatory signals can 
activate gene expression of ECM components in preadipocytes (96).  Conditioned media 
from ATMs can induce the gene expression of α-SMA in adipocyte precursors (24).   In 
this system, TGFβ signaling was required to promote a “myofibroblast” phenotype and 
TGFβ was sufficient to induce promote  induce the gene expression TGFβ can also 
induce the migration and contractility of adipose tissue fibroblasts suggesting direct links 
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between myofibroblasts and mechanical stress (90).  Secreted factors from pro-
inflammatory M1 macrophages can also block the adipogenic capacity of preadipocytes 
(19, 123).  How this may be coupled to a shift toward a myofibroblast phenotype has yet 
to be fully delineated.  Additionally, the evidence suggesting that these pro-fibrotic cells 
actually produce ECM proteins or promote their crosslinking and assembly has not been 
elucidated.  
 It is not clearly understood how the pro-fibrotic capacity overlaps with the ability of 
macrophages to degrade the ECM (131).  In other fibrotic settings, macrophages are 
important in degrading the collagen network, and in adipose tissue, ATMs have been 
shown to have significant ECM remodeling potential in obesity (198).  Still, it is unclear 
if the promotion of ECM degradation pathways (e.g. MMP production) seen in obesity 
can be resolved even with excessive accumulation of ECM. 
 
Significance of adipose tissue ECM research 
 
 Pre-clinical mouse models suggest an integrated model of macrophage control of 
adipose tissue fibrosis.  In lean states, resident ATMs participate in the maintenance of 
adipose tissue by promoting regenerative adipogenesis and ECM remodeling to permit 
adipocyte expansion and contraction upon demand.  Obesity challenges the balance of 
this system by inducing adipocyte hypertrophy and stress, which promotes M1 ATM 
accumulation and reprogramming of the M2 ATM population.  Pro-fibrotic signals from 
ATMs (either CD11c+ or resident) promote the conversion of preadipocytes to a pro-
fibrotic phenotype that promotes ECM deposition.  Fibrosis increases the mechanical 
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stress upon the adipocytes and preadipocytes that further potentiates adipocyte 
dysfunction and stress.  In response to the pro-fibrotic environment, ATMs attempt to 
degrade and remodel the ECM and restore the system to homeostasis.  However, in the 
face of ongoing nutritional excess, this may not be sufficient to restore normal adipose 
tissue function and thus metabolic dysfunction is promoted.   
 The understanding of ECM remodeling will have to take place in the context of 
dynamic nutrient states such as weight gain and weight loss in order to have a more 
complete understanding of the pathogenesis of metabolic disease. In addition, how 
remodeling differs between visceral and subcutaneous fat depots may unlock the links 
between visceral adiposity and metabolic disease.  Increasing our understanding of how 
adipose tissue fibrosis is generated and if it can be resolved may provide novel 
therapeutic strategies that are needed in the face of the obesity epidemic.   
 In this dissertation, we take a step-wise approach to adipose tissue fibrosis to 
address three major gaps in knowledge relating how the ECM is modified in the context 
of weight gain and weight loss. In the following chapter, we examine the architecture and 
organization of a previously unexplored adipose tissue ECM component, the elastin 
matrix, and investigate it mechanisms of its regulation with the development of obesity. 
In the third chapter, we investigate the organization of the collagen matrix with the goal 
of identfying the cellular sources of the excess collagen production in visceral and 
subcutaneous adipose tissues, and identify a potential mechanism of stromal cell pro-
fibrotic activation. In Chapter 4, we investigate the question of whether or not fibrosis is 
reversible after weight loss by examining adipose tissue ECM architecture and 
components both before and after weight loss.  Finally, we conclude with a discussion of 
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our findings in the context of the field of obesity and diabetes research.   
 
Summary Points: 
• The ECM is a crucial component of adipose tissue that is necessary for 
maintaining adipocyte function and structural integrity 
• Insulin resistance is associated with adipose tissue inflammation, excess ECM 
deposition, and adipose tissue fibrosis. 
• Excess adipose tissue ECM may limit the ability of adipocytes to expand and 
contract in size in response to metabolic demand. 
Future Directions  
While many groups have provided a functional base of knowledge of the events 
components of adipose tissue remodeling, there are still many important unresolved 
questions in the field: 
• What are mechanisms that regulate the deposition of ECM components in across 
physiological and pathological spectrums and how does this differ between 
adipose tissue depots? 
• What causes the shift in balance resulting in favoring ECM deposition over ECM 
degradation in adipose tissue? 
• How do interactions between ATMs and preadipocytes or ATMs and mature 
adipocytes influence how the ECM is produced and modified?  
• Does weight loss reverse the fibrotic status of the adipose tissue ECM 
architecture? 
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Figure 1-1.  Adipose tissue remodeling during obesity. With nutrient excess (chronic 
or acute), numerous events are triggered that influence adipose tissue shape. A balance 
between adipocyte hypertrophy, hyperplasia, and death contributes to the nutrient storage 
capacity of a fat depot. Hypertrophy and hyperplasia are linked to angiogenic cues that 
maintain nutrient availability to adipocytes. Adipocyte death is a trigger for the 
accumulation of inflammatory adipose tissue macrophages (ATMs) that form crown-like 
structures (CLSs), which is a hallmark of adipose tissue stress. Extracellular matrix 
(ECM) degradation and deposition in the microenvironment are regulated differently in 
these conditions. Abbreviations: CD11c+, cluster of differentiation 11c or integrin alpha 
X; HIF, hypoxia-inducible factor; MMP, matrix metalloproteinase; TIMPs, tissue 
inhibitors of metalloproteinases; VEGF, vascular endothelial growth factor. 
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Figure 1-2.  Dynamic regulation of adipose tissue extracellular matrix (ECM) with 
obesity. In lean states, the adipose tissue ECM is remodeled in response to acute 
physiologic changes in nutrient availability. This remodeling permits adipocyte 
expansion and contraction in response to nutrient demands. Both conditions require a 
relative dominance of processes that degrade the ECM over those that deposit ECM. 
With chronic obesity, this system is altered. In concert with a decrease in insulin 
sensitivity and inflammation, ECM accumulates around adipocytes. This increases 
mechanical stress by tipping the balance away from ECM degradation and toward ECM 
deposition. In concert with this, adipose tissue macrophages (ATMs) are activated and 
accumulate in ECM-dense regions. The net effect is a loss of adipocyte flexibility as a 
nutrient storage depot, which contributes to the development of metabolic disease and 
insulin resistance. Abbreviations: CLS, crown-like structure; M1 ATM, classically 
activated macrophage. 
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Figure 1-3.  Adipose tissue macrophages (ATMs) and the regulation of adipose 
tissue remodeling. ATMs sit at the interface of many of the pathways that regulate 
adipocyte health. Adipogenesis is promoted by resident alternatively activated 
macrophage (M2) ATM signals (e.g., osteopontin) and is suppressed by pro-
inflammatory cytokines from classically activated macrophage (M1) ATMs. Blockade of 
adipogenic potential can trigger a myofibroblasts or “pro-fibrotic” phenotype in 
preadipocytes by M1 ATM-secreted factors. Adipocyte death is a potent adjuvant for M1 
ATM activation, which promotes abnormal extracellular matrix (ECM) organization and 
fibrosis in conjunction with formation of myofibroblasts. Abbreviations: IL-6, 
interleukin-6; TGFβ, transforming growth factor beta; TNFα, tumor necrosis factor 
alpha. 
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Chapter 2. 
 
Obesity-Induced Remodeling of the Adipose Tissue Elastin Network is  
Independent of the Metalloelastase MMP-12 
 
Abstract 
 
The ECM plays important roles in maintaining adequate adipose tissue function 
and in metabolic regulation. Here we have examined the organization of a relatively 
unexplored adipose tissue ECM component, elastin and its response to diet induced 
obesity in mice. Additionally, we have explored the regulation and requirement of 
macrophage metalloelastase, MMP-12, in adipose tissue ECM remodeling in obesity. In 
visceral fat depots, elastin fibers form a mesh-like net that becomes denser with diet-
induced obesity. In contrast, the elastin fibers in subcutaneous adipose depots are more 
linear in organization, and are tightly associated with ATMs. We found that Mmp12 is 
produced predominantly by ATMs and can be induced with both short- and long-term 
high fat diet challenge and rapid remodeling induced by lipolysis. This contrasts with 
Mmp14 and Timp1, which are further induced only after chronic obesity in non-ATM 
populations.  We examined obese transgenic Mmp12-/- mice and found an increase in 
Portions	  of	  this	  chapter	  are	  in	  press:	  Martinez-­‐Santibanez	  G,	  	  Singer	  K,	  Cho	  KW,	  Delproposto	  J,	  Mergian	  T.,	  	  Lumeng	  CN.	  Obesity-­‐induced	  remodeling	  of	  the	  Adipose	  Tissue	  Elastin	  Network	  is	  Independent	  of	  the	  metalloelastase	  MMP-­‐12.	  Adipocyte	  2014.	  	  
31	  	   	  
gene expression of ECM genes with diet-induced obesity, but showed few significant 
differences in metabolic parameters, elastin matrix density, or in adipose tissue 
inflammation. Together, these studies reveal the architecture and diet-induced regulation 
of the elastin matrix and suggest that MMP-12 is not required for elastin matrix 
remodeling or for the metabolic dysfunction that occurs with obesity. 
 
Introduction 
 
The proper function of adipocytes is dependent on stromal cells in adipose tissue, 
as well as the organization and composition of the ECM. Adipose tissue ECM is 
composed of a diverse network of proteins that include collagens (Type I, III, V, and VI), 
fibronectin, and elastin (53). The healthy physiologic expansion of adipose tissue requires 
a tightly regulated balance of ECM deposition, degradation, and post-translational 
modifications (40, 41). Obesity promotes ECM accumulation in adipose tissue, which can 
contribute to fibrosis and ultimately impair its function as an efficient nutrient storage 
organ (81). Associations between adipose tissue fibrosis and metabolic disease has led to 
a considerable interest in understanding the mechanisms that regulate adipose tissue 
ECM remodeling (203).    
Elastin is an ECM protein found in almost all tissues, but there is a paucity of 
information regarding its distribution and regulation in adipose tissue.  Elastin is a 
heavily cross-linked protein that enables tissues to stretch and return back to its original 
conformation (76, 98).  In human adipose tissue, the density of the elastin network was 
higher in tissues from lean individuals compared to obese individuals, suggesting 
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remodeling of the elastin network with increased adiposity (197). An interaction between 
collagen and elastin networks in adipose tissue has been suggested, as elastin expression 
is decreased in Collagen VI-deficient mice, which have a less dense collagen matrix that 
is permissive to adipocyte hypertrophy (97).  Inhibition of lysyl oxidase, an enzyme that 
crosslinks both collagen and elastin fibers, can improve metabolic parameters in obese 
animals (65, 128). In addition to this structural role, elastin-derived peptides have been 
shown to contribute to insulin resistance by blocking glucose uptake in muscle and 
adipose tissue (22). 
The degradation of the ECM proteins such as collagen and elastin is controlled by 
proteinases that include matrix metalloproteinases (MMPs) and their endogenous 
inhibitors such as tissue inhibitors of metalloproteinases (TIMPs) (34, 119).  We focus on 
MMP-12 is a metalloelastase because it has the capacity to degrade elastin, and because it 
plays important roles in tissue fibrosis and injury in other tissues (71, 83, 230). Mmp12 
expression is highly induced in adipose tissue of mice with diet-induced obesity, and its 
expression has been reported in both mature adipocytes as well as in ATMs (34, 82, 132, 
192). The importance of Mmp12 in obesity-induced metabolic dysfunction remains 
unclear as one report failed to identify any metabolic phenotype in Mmp12-/- mice despite 
a decrease in ATMs and another found that Mmp12 deficiency provided protection from 
metabolic dysfunction and obesity-induced adipose tissue inflammation (14). 
In this chapter, we describe an extensive network of elastin fibers in adipose 
tissue that are regulated by diet-induced obesity. Elastin deposition is increased in 
visceral adipose tissue depots with obesity and there are significant qualitative 
differences in the cross linking of elastin fibers between depots.  Since we observe a 
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strong physical association between ATMs and elastin we have examined the response to 
dietary obesity in Mmp12-/- mice and observe changes in ECM gene expression but no 
significant change in metabolic measures with Mmp12 deficiency. 
 
Materials and Methods 
 
Animal Studies.  
C57BL/6J and B6.129X-Mmp12tm1Sds/J (Mmp12-/-) mice were obtained from The 
Jackson Laboratories. Male C57 mice, (6 weeks of age) were fed a normal diet (ND, 
4.5% fat Research Diets, New Brunswick, NJ), or High fat diet (HFD, 60% fat from lard; 
Research Diets). For Mmp12-/- experiments, littermate males were fed a HFD ad libitum 
starting at 8 weeks of age. For lipolysis experiments, mice fed a ND or HFD for 16 weeks 
were injected with 1mg/kg of CL316243 or PBS-vehicle intraperitonealy (IP) for three 
consecutive days. All procedures were approved by the University of Michigan 
University Committee on Use of Care of Animals and were in compliance with the 
Institute of Laboratory Animal Research Guide for the Care and Use of Laboratory 
Animals.  
 
Quantitative real-time PCR.  
Tissues were frozen in liquid nitrogen and stored at -80°C. Total RNA was 
isolated from adipose tissues, SVCs, or FACS-sorted cells using the RNeasy Lipid Tissue 
Kit or QIAzol lysis reagent (Qiagen, Valencia, CA) followed by DNAse digestion 
according to manufacturer’s instructions. cDNA was generated from 0.5-1ug of RNA 
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using the High Capacity cDNA Reverse Transcription Kits (Applied Biosystems, 
Carlsbad, CA). Real-time PCR analysis was performed using SYBR Green PCR Master 
Mix (Applied Biosystems) and StepOnePlus thermocycler (Applied Biosystems). 
Relative expression was performed in duplicate samples and determined using the 2- Δ
elatimethod after normalizing to Arbp.  Mmp12 to Timp1 ratios calculated by dividing 
Mmp12 relative expression levels by Timp1 relative expression levels.  
 
Microscopy and Histology.  
Tissues used for sectioning were fixed and stored in 10% Buffered Formalin. 
Anti-Elastin antibodies for immunofluorescence staining were kindly provided by Dr. 
Robert Mecham (Washington University in St. Louis). Macrophages were stained with 
anti-MGL-1 (AbCam) or anti-Mac-2 (eBiosciences) antibodies. Whole mount 
immunofluorescence microscopy was performed as described (123).  Images were 
captured using an Olympus inverted microscope fitted with an Olympus DP72 camera. 
ImageJ software (NIH) was used to measure adipocyte size and to assemble composite 
images. Mean Linear Intercept (MLI) was used to measure the mean free distance 
between elastin matrix fibers, and was performed by point counting method as described 
(103).  Elastin positive area (%Eln+ area) was calculated with ImageJ software.  
 
Analysis of adipose tissue stromal vascular fraction (SVF).   
SVF isolation and flow cytometry were performed as described (144). Antibodies 
used were: CD45-eFluor405, CD64-PE, and CD11c-APCCy7, F480-APC, CD11b-
APCCy7, in addition to propidium iodide viability stain. Flow Cytometry was performed 
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using a FACS CANTO II Flow Cytometer (BD Biosciences) and sorting on a FACSAria 
III.  Analysis with FlowJo software (Tree Star, Ashland, OR). 
 
Metabolic studies.  
 Glucose and Insulin tolerance tests were performed as described (143). 
Plasma insulin levels were measured using a mouse insulin ELISA kit (Crystal Chem, 
Downers Grove, IL). Body composition analysis (body fat, lean mass, free fluid) was 
performed by the Animal Phenotyping Core at the University of Michigan’s Nutrition 
and Obesity Research Center using the NMR-based analyzer (Minispec LF90II, Bruker 
Optics). 
 
Statistical analysis.  
 Data are expressed as the mean +/- the standard error of the mean (SEM). 
GraphPad Prism software (GraphPad Software, La Jolla, CA) was used for statistical 
analyses. Differences between groups were determined using unpaired two-tailed 
Student’s t-test, where a p≤0.05 was considered significant.  
 
Results 
 
Adipose tissue depot specific differences in the organization of the elastin matrix 
While the collagen network is relatively well characterized in adipose tissue, little 
is known about the distribution of the adipose tissue elastin network and how this 
changes with obesity.  We assessed elastin composition in adipose tissue using several 
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complementary methods.  First, Verhoeff’s stain, previously used to identify elastin in 
other tissues, was performed on section from visceral (epididymal; eWAT) and 
subcutaneous (inguinal; iWAT) white adipose tissue depots from lean (16wks ND) and 
obese (16wks HFD) male C57BL/6 mice. In lean mice, Verhoeff+ regions were more 
prominent in iWAT compared to eWAT (Figure 2-1A).  With obesity, Verhoeff+ areas 
increased in eWAT and were concentrated around crown-like structures (CLSs) - regions 
of adipocyte death and ATM accumulation. In contrast, iWAT from obese mice had 
reduced Verhoeff+ regions relative to lean tissues. To verify the specificity of Verhoeff’s 
stain for elastin, we performed immunohistochemistry (IHC) for elastin on eWAT and 
iWAT from lean and obese (Figure 2-1B). In eWAT, elastin+ regions were increased 
with HFD and recapitulated the observations with Verhoeff stain.  Less elastin+ staining 
was observed in iWAT compared to eWAT and there were no significant changes in 
elastin positivity in iWAT with HFD.  The iWAT staining did not match the Verhoeff’s 
reagent and suggests non-specific staining in iWAT may limit the use of the Verhoeff’s 
reagent.  
As a third approach, elastin was assessed in fixed whole mount adipose tissue 
samples by immunofluorescence microscopy.  Elastin fibers in eWAT of ND mice 
formed a highly cross-linked mesh-like network around adipocytes (Figure 2-2A).  In 
stark contrast, elastin fibers in iWAT were organized in individual fiber bundles with less 
cross-linking compared to eWAT (Figure 2-2B).  After 16 weeks of HFD, the elastin 
network in eWAT showed an increase in the density of elastin fibers and with more 
intersecting fibers (Figure 2-2C). The iWAT elastin network in obese mice also 
demonstrated a qualitative increase in intersecting fibers (Figure 2-2D).  Quantification 
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of elastin+ regions confirmed the increase in elastin fibers in eWAT, but not iWAT with 
HFD (Figure 2-2E). The mean linear intercept (MLI) method was utilized to quantify 
reticulation (increased branching is associated with a decrease in MLI) (8, 126).  This 
demonstrated a significant increase in elastin branching in eWAT compared to iWAT and 
an increase in branching with HFD feeding (decrease in MLI) (Figure 2-2F). No 
significant changes in elastin (Eln) gene expression were seen in eWAT or iWAT 
suggesting that post-transcriptional regulation of elastin degradation/formation may be a 
critically regulated step (Figure2-2G). 
 
Mmp12 expression is induced in ATMs with obesity.  
MGL1+ resident ATMs are found in all adipose tissue depots and are the 
dominant macrophage population in lean mice (124). In iWAT, MGL1+ ATMs were 
observed to be tightly associated with elastin fibers (Figure 2-2H). The close physical 
association between ATMs and elastin fibers led us to explore the hypothesis that 
macrophages may participate in the remodeling of the elastin matrix via the macrophage 
metalloelastase MMP-12.  
We examined Mmp12 expression in four adipose tissue depots (eWAT, iWAT, 
peri-renal adipose tissue (rWAT) and mesenteric adipose tissue (mWAT)) after a short, 
4-week HFD challenge to induce rapid fat expansion. This short term HFD treatment 
induced significant adipose tissue expansion without accumulation of CD11c+ ATMs 
(data not shown).  Gene expression analysis revealed that Mmp12 was induced at least 80 
fold in all four depots after HFD challenge when compared to lean age-matched ND-fed 
controls (Figure 2-3A). In contrast, the expression of Timp1, an endogenous inhibitor of 
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MMP-12, was not altered by obesity in eWAT or iWAT, but was induced in mWAT and 
rWAT depots (Figure 2-3B).  Expression of Mmp14, a pericellular collagenase, 
decreased in eWAT with short term HFD, but did not change in other depots (Figure 2-
3C).   Long-term HFD (16wks) induced both Mmp12 and Timp1 expression in eWAT 
(Figure 2-3D,E). Mmp14 increased in eWAT after HFD (Figure 2-3F).    
Based on the range of reports in the literature, we next set out to clarify the source 
of Mmp12 expression in adipose tissue after diet-induced obesity. We analyzed Mmp12 
gene expression from total adipose tissue or from adipose tissues that had been 
fractionated to separate mature adipocytes and the stromal vascular fraction (SVF). 
Consistent with previous reports, the SVF was identified as the major site of Mmp12 
induction (Figure 2-4A).  FACS cell sorting was then used to separate ATMs 
(F4/80+CD11b+) and Non-ATMs from the SVF. Mmp12 expression was enriched in the 
ATM sub-fraction from both lean and obese groups and was induced by HFD only in the 
ATM sub-fraction. (Figure 2-4B) In contrast, the expression of Timp1 and Mmp14 were 
more prominently expressed in the non-ATM sub-fraction, where they were both induced 
with HFD (Figure 2-4,-D).   Overall, our data demonstrate a rapid induction of Mmp12 in 
ATMs with fat expansion that precedes other genes involved in ECM remodeling. 
 
Lipolytic remodeling activates Mmp12 expression.  
To observe rapid adipose tissue remodeling in a different context, we employed 
the use of an acute lipolysis model (106).  To examine the regulation of Mmp12 gene 
expression in this setting, we assessed age-matched lean (ND) and obese (16-week HFD) 
mice after three days of treatment with a d  adrenergic receptor agonist, CL-316243 (CL).  
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Compared to lean vehicle-treated controls, Mmp12 was induced by CL compound 
(Figure 2-5A).  In obese mice, Mmp12 was highly expressed compared to lean controls, 
however CL did not induce further Mmp12 expression in obese mice. CL had no 
significant effects on Timp1 expression or Mmp14 expression in lean or obese mice 
(Figure 2-5B,C).  
 
Mmp12 deficiency does not alter weight or metabolism with high fat diet feeding.  
From our observations, we hypothesized that MMP-12 would play a critical role 
in modifying the elastin matrix to permit adipocyte hypertrophy in response to high 
calorie diets and obesity.  Therefore, we tested the impact of Mmp12 deficiency on 
adiposity and measures of metabolic dysfunction and inflammation in adipose tissue. To 
assess this, Mmp12-/-, Mmp12+/-, and Mmp12+/+ littermates were fed ND or HFD for 10 
weeks. In adult lean mice, there were no significant differences in body weight or glucose 
metabolism as seen by fasting glucose measurements (data not shown).  In the HFD fed 
group, Mmp12-/- and Mmp12+/- mice had higher body weights compared to Mmp12+/+ 
during the later stages of HFD feeding (Figure 2-6A). However, body composition 
analysis showed no significant differences in percent lean or fat mass. To evaluate 
glucose regulation, we measured fasting glucose and insulin levels, and performed 
glucose and insulin tolerance tests and observed no significant differences between 
genotypes (Figure 2-6B). Tissue weights of the liver, eWAT, iWAT, and rWAT fat 
depots did not differ between genotypes, indicating that adipose tissue expansion was not 
dependent upon Mmp12 (Figure 2-6C).  Adipocyte size (Figure 2-6D) and density (# of 
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adipocytes per gram, not shown) did not differ between genotypes, nor did expression of 
the markers of adiposity Lep or AdipoQ (Figure 2-6E). 
To evaluate if Mmp12 plays a role in chronic obesity and metabolism, we fed 
Mmp12-/- and Mmp12+/+ HFD for 25-27 weeks.  In contrast to short term feeding, no 
significant differences in body weight, body composition, fat pad weights, or glucose 
tolerance were observed between genotypes (data not shown). Together, these data 
suggest that an Mmp12 deficiency does not play a significant role in adipose tissue 
expansion, metabolism, or chronic obesity.  
 
Mmp12 deficiency does not influence ECM deposition or ATM accumulation  
We assessed long term HFD fed Mmp12-/- and Mmp12+/+ mice for adipose tissue 
ECM and did not observe significant differences in the deposition of total collagen as 
measured by Picrosirius collagen stain (data not shown). Similarly, we did not see 
differences in the organization of the elastin matrix in eWAT as measured by Verhoeff’s 
stain (Figure 2-6F).   Because Mmp12 may impact ATM function, we examined CLS 
formation and observed a mild qualitative decrease in the number of Mac-2+ CLS in 
eWAT of Mmp12-/- animals similar to other reports (Figure 2-6G) (14).  However, flow 
cytometry analysis failed to detect any differences in the quantity of CD11c+ ATMs and 
CD11c- resident ATMs in long term HFD fed Mmp12+/+ and Mmp12-/- mice (data not 
shown).  
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Mmp12 deficient animals express higher levels of ECM genes 
Finally, we assessed if Mmp12 deficiency influences ECM gene expression in 
adipose tissue.  From the eWAT from HFD- fed Mmp12-/- and Mmp12+/+ mice, small but 
statistically significant increases in the expression of Col1a, Col5a, Col6a3, and Tgfb1 in 
eWAT of Mmp12-/- mice were observed (Figure 2-7A). We did not observe differences in 
expression of genes involved in crosslinking ECM components and ECM processing 
(Figure 7B).  Evaluation of genes related to macrophage migration and inflammation in 
adipose tissue showed an increase in Csf1, but a decrease in Mrc1 gene expression (a 
marker of alternatively activated macrophages) (Figure 2-7C). No significant differences 
in expression of chemokine genes were observed (Figure 2-7D).  
 
Discussion 
 
The makeup of the adipose tissue ECM has the potential to influence whole-body 
metabolism by modifying the ability of adipocytes to store nutrients. Of the ECM 
components, adipose tissue elastin is one of the least understood. Elastin has unique 
mechanical properties that provide tissue flexibility and resilience to deformation (5).  
Our findings demonstrate 1) a distinct depot-specific architecture of the elastin network 
in adipose tissue with more a dense network of elastin fibers in visceral compared to 
subcutaneous adipose tissues, 2) speculation of the use of elastin fibers perhaps as a 
scaffold by ATMs, 3) ATMs are the main source of the metalloelastase Mmp12 that is 
induced with lipolysis, short term, and chronic HFD challenge, and 4) obese Mmp12-/- 
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mice have increase expression of ECM genes, but do not demonstrate significant 
differences in glucose metabolism or adipose tissue inflammation compared to WT mice.   
In several tissue fibrosis settings, the density of elastin has been shown to increase 
after injury (21, 226). Our results match a study reporting the pericellular localization of 
heterogenic elastin fibers around adipocytes (5). Our results add further detail about its 
organization and changes with obesity and suggest the importance of post-translational 
regulation of elastin stability and fiber organization in adipose tissue. The stark 
differences in elastin organization and mesh density between the visceral and 
subcutaneous depots may shed some light into why the expansion and inflammatory 
potential of these two fat pads are different. We posit that the organization of elastin 
fibers may be responsible for the metabolic and inflammatory differences between 
visceral the subcutaneous adipose depots. 
Our immunostaining revealed the surprising observation that many resident 
ATMs are bound to elastin fibers, and was more clearly observed in subcutaneous depots.  
This may fall in line with observations that elastin and its fragments can stimulate 
macrophage chemotaxis (84, 91). ATMs may be using elastin fibers as an organizing 
scaffold or alternatively located there poised to degrade or remodel the elastin network.  
To further study the role of MMP-12 in adipose tissue, we challenged Mmp12-/- 
mice to short term and long term HFD. We observed a small increase in total body 
weight in the Mmp12-/- mice compared to WT controls with the short-term treatment.  
This effect was not observed with a longer HFD challenge.  Our short term diet challenge 
results are comparable to the study by Lee et al , however our studies differ because they 
demonstrated a profound increase in adipose tissue mass in Mmp12-/- mice which we did 
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not observe (111).   It is unclear why the body weight differences did not persist with 
chronic feeding in our studies.  In both cohorts however, we did not observe significant 
metabolic differences related to Mmp12 deficiency. This observation concurs with 
Bauters et al which show no metabolic phenotype despite an decrease in ATMs, and 
conflicts with Lee et al who suggest that Mmp12 plays a role in aggravating insulin 
resistance (14, 111).  Differences in experimental design and husbandry conditions (e.g. 
microbiome) may explain our differing results.  Bauters et al used a mouse strain on a 
mixed genetic background.  Lee et al used Mmp12-/- animals on a C57BL/6 background, 
yet it is unclear if littermate controls were used.  We feel that the use of littermate and 
heterozygous controls is required to control for husbandry conditions.   
The observation that Mmp12 is robustly and rapidly induced with lipolytic and 
obesogenic stimuli in iWAT may be consistent with a requirement for elastin to be 
remodeled to permit adipocyte morphological changes such as with hypertrophy.  
However, from our mouse studies, it appears that overall Mmp12 is dispensable in the 
overall regulation of the elastin network.  Our findings further emphasize the importance 
of overlapping and redundant function of MMPs and other ECM remodeling enzymes.  It 
suggests that other elastases such as cathepsins and neutrophil elastases which have been 
implicated in obesity and metabolic disease may play a more prominent role in ECM 
reorganization (205, 238). Overall, while we have added further detail in one of the 
components of the adipose tissue ECM, our data suggests that MMP-12 may not play a 
significant role in regulating the elastin matrix, metabolism, or in modifying adipose 
tissue macrophage recruitment or phenotypes in mice.  
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Figure 2-1. High fat diet-induced obesity modifies the adipose tissue elastin matrix.  
Paraffin embedded sections were stained with (A) Verhoeff Van Giesonlism, or in 
modifying adipose tissue macrophage recruitment or phenotypes in mice. of MMPs and 
other ECM remodeling enzymes.  It sugges) mouse epididymal (eWAT) and 
subcutaneous inguinal (iWAT) tissues. Representative images shown from one of 5 
replicate samples with similar results.  (scale bar = 100μM).  
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Figure 2-2. Elastin matrix architecture differences between visceral and 
subcutaneous tissues. Immunofluorescence imaging of elastin (red), resident ATMs 
(MGL1; green), and blood vessels (Isolectin; Blue). (A,B) Representation of whole 
mount tissues from lean (ND) eWAT and iWAT and (C,D) obese (HFD) eWAT and 
iWAT. (scale bar = 50μM). (E) Graphical representation of percent elastin positive 
(%Eln+ area) and (F) reticulation by Mean Linear Intercept (MLI). (G) Gene expression 
analysis of Elastin from eWAT from ND and HFD animals. (H) Representative image of 
ATMs bound to Elastin matrix (scale bar = 100μM). (mean ± SEM; n= 2-4 per 
group*p<0.05) 
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Figure 2-3. Mmp12 is dynamically regulated in adipose tissue with short term and 
long-term diet induced obesity. Analysis of (A) Mmp12, B) Timp1, and (C) Mmp14 
gene expression in major fat pad depots (mWAT = mesenteric, rWAT = perirenal) from 
lean (ND) and obese (HFD) mice after 4 weeks (n=4). (D-E, G) eWAT gene expression 
analysis for (D) Mmp12, (E) Timp1, and (F) Mmp14 from animals on ND or HFD for 16 
weeks. (mean ± SEM; n=4-6 per group, *p<0.05, **<0.01***0.001, ****0.0001) 
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Figure 2-4. Mmp12 is primarily induced in adipose tissue macrophages with HFD. 
(A) Expression of Mmp12 from total eWAT, dissociated adipocyte fraction (Adipo), and 
the stromal vascular fraction (SVF) normalized to total ND eWAT levels.  Expression 
analysis of (B) Mmp12, (C) Timp1, and (D) Mmp14 from FACS sorted eWAT SVF. 
(ATMs= Black bars, F4/80+ CD11b+, Non-ATMs = White bars, F4/80-CD11b-). (mean ± 
SEM; n=4 per group, *p<0.05, **<0.01***0.001, ****0.0001)  
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Figure 2-5. Model of acute lipolysis induces Mmp12 in visceral adipose tissues.  Gene 
expression analysis of (A) Mmp12, (B) Timp1, and (C) Mmp14 in eWAT from ND (white 
bars) and HFD (black bars) fed mice after I.P. injection of CL-316243 (CL) for 3 days. 
(mean ± SEM; n=3 per group, *p<0.05) 
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Figure 2-6. Mmp12 deficiency does not influence body composition or metabolism.  
(A) Body weights were measured in male Mmp12-/-, Mmp12+/-, and Mmp12+/+ mice fed 
HFD for 10 weeks, body composition was measured at 8 weeks of HFD. (B) Glucose 
Tolerance Tests (GTT), Insulin tolerance tests (ITT), and fasting serum insulin 
concentrations were examined. (C) eWAT weights were recorded after sacrifice, and (D) 
a graphical representation of adipocyte number by size was recorded. (D) AdipoQ and 
Lep gene expression was examined. (F) Verhoeff’s stain and (G) immunofluorescence 
stain for Mac-2+ ATMs in HFD-fed Mmp12-/- mice and wild type controls shown in gray 
scale. (scale bar = 100μm)  (mean ± SEM; n=4-10).  
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Figure 2-7. Gene expression analysis of markers of extracellular matrix remodeling 
in Mmp12-/- mice. Mmp12+/+ data shown in white bars, Mmp12-/- in black bars. (A,B) 
Gene expression analyses of ECM remodeling-related genes and markers of ECM 
maturity and crosslinking, (C,D) inflammatory cytokines and chemokines are shown 
(mean ± SEM; n=4-8, *p<0.05, **<0.01***0.001).  
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Chapter 3.  
 
Diet-Induced Obesity Expands Collagen-I+ Preadipocyte Populations in Mice 
 
Abstract 
 
  The density of the adipose tissue ECM increases with chronic obesity and can 
lead to adipose tissue fibrosis, which is associated with insulin resistance and metabolic 
disease. Adipose tissue fibrosis correlates with the accumulation of ATMs and stromal 
cells in matrix-dense regions, however these interactions are not well defined. Here, we 
set out to identify stromal factors contributing to ECM production and the mechanisms 
by which this program is activated in diet-induced obesity. Adipose tissue fibrosis was 
noted to be prominent in visceral but not subcutaneous depots only after prolonged high 
fat diet feeding.  Microarray analysis and identification of Collagen I+ preadipocytes by 
flow cytometry demonstrate that preadipocytes are the major source of collagen I 
production with diet-induced obesity.  ColI+ preadipocytes accumulated in visceral fat 
pads to a greater extent than subcutaneous fat pads.  Secreted factors from visceral, but 
not subcutaneous adipose tissue induced collagen I in preadipocytes, and TGF -1 was 
identified as a likely candidate for this as it is induced in ATMs in obese mice.  In vitro 
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experiments revealed that alternative activated macrophages, but not classical or 
metabolically activated macrophages induced expression of fibrillar type I collagen in 
primary preadipocytes via TGFu-1 signaling pathway. We conclude that preadipocytes 
are the main source of collagen I expression and implicate TGFß-dependent signals 
between macrophages and preadipocytes in triggering adipose collagen I production.  
 
Introduction 
 
Obesity is a strong risk factor for type 2 diabetes and is associated with metabolic 
disturbances relating to nutrient sensing and regulation (166). Adipose tissue is the 
body’s main energy repository and one of its most important functions is to store and 
release nutrients according to metabolic demand (112). The progression from a lean to an 
obese state involves changes in adipose tissue structure that include adipocyte 
hypertrophy (increased cell size) and hyperplasia (new adipocyte formation) (202). This 
transformation is regulated by cells that include preadipocytes, endothelial cells and 
immune cells such as macrophages.  Many of these adipose tissue stromal cells undergo 
quantitiative and qualitative changes with obesity and contribute to the development of 
insulin resistance and progression to diabetes (12, 63, 235).   
The ECM plays a pivotal role in adipose tissue remodeling events and comprises 
a substantial portion of the adipose tissue non-cellular bulk (133, 176, 233).  ECM 
remodeling, the active deposition and degradation of the ECM proteins, plays crucial 
roles in adipogenesis, adipocyte function, and adipose tissue structural integrity (41, 42, 
53). Adipose tissue ECM is comprised of many structural protein and carbohydrate 
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components, predominantly the family of collagens – both fibrillar (e.g. Type I) and non-
fibrillar (e.g. Type VI) (53, 133, 170). With obesity, an imbalance of ECM deposition, 
degradation, and crosslinking of ECM compounds results in higher accumulations of 
insoluble collagen fibrils, often referred to as adipose tissue fibrosis. Adipose tissue 
fibrosis is a hallmark of obesity and is a feature of metabolically dysfunctional adipose 
tissue (53, 198, 203).  Obesity induces the expression of a wide range of genes related to 
ECM production (20, 74). While it is widely accepted that the interstitial deposition of 
fibrotic material is associated with obesity, mechanisms by which fibrosis develops and 
at what point the excess deposition becomes a pathological concern are still unresolved 
(53, 134).   
Pre-clinical studies suggest that the dense ECM deposition seen with adipose 
tissue fibrosis limits the ability of preadipocytes to differentiate and form new adipocytes 
and of adipocytes to hypertrophy with nutrient excess (41, 42, 198). In this setting, 
adipocytes fail to efficiently store nutrients as fatty acids leading to ectopic lipid 
deposition in tissues such as the liver and muscle, with negative effects on whole-body 
metabolism (75). Decreasing ECM deposition by genetic deletion of non-fibrillar 
collagen type VI was shown to permit adipocyte hypertrophy and improve whole-body 
glucose metabolism in mice (97).  The relationship between adipose tissue fibrosis, ECM, 
and structural measures in humans may be more complex, but ECM physiology has been 
shown to differentiate healthy and unhealthy obese individuals (1, 108). 
In other fibrotic diseases, ECM deposition is associated with tissue damage and a 
local inflammatory reaction driven by leukocytes.  The inciting factor in obese adipose 
tissue may be physical and mechanical stress of enlarged adipocytes.  For reasons still 
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now known, this hypertrophy is associated with the activation of leukocytes such as mast 
cells and macrophages (75, 198) that may promote a fibrotic response. ATMs are 
heterogeneous and are best known for their roles in regulating chronic inflammation and 
their contribution to the development of insulin resistance (12, 122, 228).  Resident tissue 
ATMs are present in lean and obese states and express markers of M2 or alternatively 
activated macrophages and may play an immunosuppressive role to prevent inflammation 
and facilitate preadipocyte differentiation (160).  Obesity induces the generation of 
CD11c+ ATMs with some features of M1 or classically activated macrophages that have 
the capacity to inhibit adipocyte differentiation by generating pro-inflammatory signals 
(43, 125).  While many studies support the concept that the M1-M2 spectrum of 
macrophage activation contributes to metabolic disease, recent studies suggest this model 
is overly simplistic and that a distinct “metabolically active” macrophage activation state 
(MMe) is a feature of ATMs in obesity and diabetes (107, 122, 142, 149, 159).   
In many settings of tissue repair and fibrosis, macrophages play important roles as 
effectors and initiators of ECM remodeling (110, 231).  Evidence also supports an 
important role for ATMs in obesity associated ECM remodeling. There is a reported 
association of M2c “remodeling” phenotype macrophages in this context (43, 60, 96, 
198). ATMs play critical roles in the developmental growth and remodeling of adipose 
tissue (160, 191, 202).  In obese states, ATMs co-localize with preadipocytes in regions 
undergoing remodeling and new adipocyte formation (114). Macrophage-secreted factors 
such as inhibin beta A, a TGFß family member, have been identified as factors secreted 
from classically activated macrophages that induce a pro-fibrotic phenotype in 
preadipocytes (60, 96).  However, the influence of the range of macrophage activation 
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states on preadipocyte fibrosis and the importance of these cells in the fibrotic response 
are unresolved.   
Here, we investigate the regulation of ECM in adipose tissue in mouse models of 
diet-induced obesity (DIO) with the goal of identifying the cells responsible for ECM 
deposition with obesity and to understand their regulation. Using novel flow cytometry 
techniques to identify collagen-expressing adipose stromal cells, we support a primary 
role for preadipocytes in the induction of fibrillar type I collagen production with DIO. 
We have examined how macrophage-derived signals influence preadipocyte ECM 
production and demonstrate that the M2 alternative activation state, but not M1 or MMe 
activated macrophages have the strongest effect on induction of preadipocyte collagen I 
expression via TGFβ signaling.  We demonstrate that a pro-fibrotic profile in resident 
ATMs is induced in obese mice, suggesting that they are a potential source of pro-fibrotic 
signals. Our observations advance our understanding of ATM activation states and their 
supporting role in regulating adipose tissue ECM deposition, which may ultimately 
influences whole body metabolism.  
 
Materials and Methods 
 
Animal Studies 
C57BL/6J Male mice were fed ad libitum normal diet (4.5% calories from fat; 
PMI Nutrition International) or high fat diet (60% calories from fat; Research Diets) 
starting at 6 weeks of age for durations as described. Animal procedures were approved 
by the University Committee on Use and Care of Animals at the University of Michigan 
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and were conducted in compliance with the Institute of Laboratory Animal Research 
Guide for the Care and Use of Laboratory Animals. 
 
Total Collagen assessment 
Total collagen staining was performed on formalin-fixed paraffin-embedded 
tissue sections using the Picrosirus Red Stain Kit (Polysciences, Inc. Warrington, PA). 
Images were captured using an Olympus inverted microscope fitted with an Olympus 
DP27 camera. Image J software (NIH) was used to measure density. Hydroxyproline 
content was measured in 50mg of tissue input using the Hydroxyproline assay kit from 
QuickZyme Biosciences (Leiden, Netherlands, dist. Cedarlane Labs Burlington, NC).  
 
Flow Cytometry and Cell sorting 
Adipose tissues were dissociated as previously described (36). Fractionation of 
major adipose tissue populations was performed using a combination of centrifugation, 
biotinylated anti-CD31 antibodies (Affymetrix eBioscience, San Diego, CA) and lineage 
depletion kit from Milteny Biotech, Inc. (San Diego, CA). Fluorescence activated cell 
sorting was performed on cells stained CD11b+F4/80+ or CD11b-F4/80- (Affymetrix 
eBioscience, San Diego, CA) using a FACSaria (BD Biosciences, San Jose, CA). For 
intracellular collagen staining, cells were incubated in Fc Block then stained with surface 
antibodies (Affymetrix eBioscience, San Diego, CA) and Live/Dead viability stain 
(Thermo Fisher Scientific-Life Technologies, Carlsbad, CA) for leukocytes (Live/Dead-
CD64+, CD45+) preadipocytes (Live/Dead-CD31-CD45-Sca-1+, PDGFR α +) and 
endothelial cells (CD31+) for 45 min at 4°C. Briefly, intracellular stains were performed 
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using FOXP3 Fix/Perm buffer (BioLegend, San Diego, CA) followed by 15 min block 
with 0.5% goat serum, a 1hr incubation with 0.5μg of rabbit Collagen Type I antibody 
(Rockland, Limerick, PA), three washes, and 30 min incubation with 0.2μg of goat anti-
rabbit AlexaFluor 647 antibody (Thermo Fisher Scientific-Life Technologies, Carlsbad, 
CA). Flow cytometry performed on FACSCanto II Flow Cytometer (BD Biosciences, 
San Jose, CA.) and analyzed with FlowJo data analysis software (Ashland, OR).  
 
Explant tissue culture and conditioned media  
Tissue explants were cut to 150mg pieces and cultured in serum-free AIM-V 
AlbuMAX (BSA) media for 48 hours at 37°C (Thermo Scientific-Life Technologies 
Carlsbad, CA). For cytokine array analysis, tissues were cultured in serum-free DMEM 
with antibiotics for 48 hours 37°C. Explant conditioned media was pooled and assessed 
with the Proteome Profiler Cytokine Array (Panel A) (R&D systems, Minneapolis, MN). 
Immunoblots were quantified after background subtraction for integrated pixel density 
with ImageJ.  Secreted TGFβ-1 protein from tissue explants was collected in serum-free 
DMEM and measured with ELISA at the University of Michigan Cancer Center 
Immunology core facility. 
 
Cell culture experiments 
3T3-L1 mouse preadipocytes from American Type Culture Collection (Manassas, 
VA) were cultured and differentiated as described (121). Cells were treated with 
recombinant IL-1β at 10pg/mL and IL-1Ra at 40pg/mL for 48hrs (R&D systems, 
Minneapolis, MN). Primary stromal cells were cultured in 10% heat-inactivated FBS and 
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high glucose DMEM and Primocin (Invivogen, San Diego, CA). ALK5/TGFβ signaling 
inhibitor SB431542 (Tocris, Bristol, UK) was used at 100nM for 48hrs. ImageStream 
analysis was performed at the University of Michigan flow cytometry core facilities using 
ImageStreamX Mark II flow cytometer (EMD-Millipore-Amnis, Seattle, WA). 
Immunofluorescence staining was performed on 10% buffered formalin-fixed cells with 
Collagen Type I or Pro-collagen I antibody (Rockland, Limerick, PA) AlexaFluor 488 
antibody (Thermo Fisher Scientific-Life Technologies, Carlsbad, CA), aSMA-Cy3 
antibodies (Sigma-Aldrich, St. Louis, MO), and DAPI (Thermo Fisher Life 
Technologies, Carlsbad, CA). For 3T3-L1 macrophage conditioned media exposure 
experiments, 2mLs of undiluted conditioned media was added to 50K cells/well in 6 well 
dishes.  
 
Bone marrow-derived macrophages and activation  
Bone marrow cells were isolated from mice by flushing tibias and fibulas. Cells were 
differentiated into bone marrow-derived macrophages as described (195). Following 
differentiation, macrophages were activated to M1, M2, and MMe activation states as 
described (107). After 3 X 5min washes with PBS, conditioned media was collected for 
24 hours in serum-free low-glucose DMEM with antibiotics. Secreted TGFβ-1 protein 
levels were measured with ELISA at the University of Michigan Cancer Center 
Immunology core facility.  
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Gene expression analysis 
Total RNA was extracted using RNeasy Mini Kits (QIAGEN), and cDNA was 
generated from 0.5ug of RNA using high-capacity cDNA reverse transcription kits 
(Applied Biosystems). Power SYBR Green PCR Master Mix (Applied Biosystems) and 
the StepOnePlus System (Applied Biosystems) were used for real-time quantitative PCR. 
Arbp expression was used as an internal control for data normalization. Samples were 
assayed in duplicate, and relative expression was determined using the 2−ΔΔCT method.   
For microarray analysis, RNA was purified from FACS sorted viable “resident” 
(CD45+CD64+CD11c-) and CD11c+ (CD45+CD64+CD11c+).  Affymetrix microarray 
analysis (Mouse Gene ST 2.1) was performed as described in triplicate samples from lean 
and obese (HFD-fed for 16 weeks) (n=3 per group) (124).  Pathway analysis was 
performed with DAVID (79, 80).   
 
Statistical Analysis 
Data are shown as mean ± standard error of the mean (SEM). Differences 
between groups were determined using two-tailed Student t tests and one-way ANOVA 
analysis with GraphPad Prism 6.0e software. p < 0.05 was considered significant.  
 
Results 
 
Diet-induced obesity increases adipose tissue ECM deposition in visceral fat depots 
Since relatively few studies have evaluated how adipose tissue ECM changes with 
duration of high fat diet feeding over time, we performed a time course analysis of 
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C57/BL6 male mice fed either normal chow diet (ND) or HFD for 4 to 24 weeks. Body 
weights increased significantly with longer duration of HFD challenge (Figure 3-1A). 
Epididymal white adipose tissue (eWAT) weights increased with HFD and peak 
hypertrophy was reached at 12 weeks of diet challenge with a subsequent decline at later 
time points (Figure 3-1B). In contrast, subcutaneous inguinal white adipose tissue 
(iWAT) tissue weights peaked later after 16 weeks of diet challenge before stabilizing 
(Figure 3-1C).  
To evaluate if collagen accumulation was a possible contributor to the differences 
in adipose tissue hypertrophy, we examined collagen deposition via picrosirius red total 
collagen stain at 12 and 24 weeks of diet (Figure 3-1D). HFD induced a qualitative 
increase in pericellular collagen staining around adipocytes in eWAT at 12 weeks that 
increased at 24 weeks. Also observed as an increase in smaller adipocytes reminiscent of 
new adipogenesis. In iWAT however, we did not observe a qualitative increase in 
collagen based on picrosirius red staining with obesity.  This data suggests that in diet 
induced obesity models, total collagen density is a feature that appears in eWAT prior to 
iWAT and correlates with a limitation in adipose tissue hypertrophy.   
Biochemical assessment of hydroxyproline was used on adipose tissue samples to 
quantify total collagen content in eWAT from animals fed HFD. Compared to age 
matched ND mice, 8 weeks of HFD induced a decrease in collagen content in eWAT.  
eWAT samples from mice fed a HFD for longer durations demonstrated a trend towards 
an increase in hydroxyproline content (Figure 3-1E). Hydroxyproline content in iWAT is 
lower after 16 weeks of HFD (Figure 3-1F).  Gene expression analysis of fibrillar 
Col1a1 and non-fibrillar Col6a3 in eWAT demonstrated the induction of both genes after 
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8 weeks of HFD exposure that correlates with the histologic analyses (Figure 3-1G). 
Conversely, we observed a downward trend of expression of these ECM components in 
iWAT with HFD. These findings highlight the depot specific differences in the 
association between adipose tissue fibrosis and limitation in fat expansion.  
 
Collagen expression decreases with adipocyte differentiation 
Despite the evidence supporting increases in adipose tissue ECM gene expression 
and density in eWAT with obesity, the cellular sources of ECM production in adipose 
tissue are not clearly delineated. To investigate this in preadipocytes/adipocytes, we 
evaluated the dynamics of ECM gene expression in preadipocytes as they differentiate to 
lipid-laden adipocytes. 3T3-L1 preadipocytes were differentiated for 0, 3, 6, or 9 days 
and gene expression analysis was performed. During the course of differentiation, the 
expression of fibrillar collagen I (Col1a1) decreased as did the expression of lysyl 
oxidase (Lox), a key enzyme that crosslinks collagen and elastin fibers to mature the 
ECM (Figure 3-2A) (45). In contrast, the expression of non-fibrillar collagen VI 
(Col6a3) was more prominent in mature adipocytes compared to preadipocytes. These 
data suggest that undifferentiated preadipocytes express more fibrillar Col1a1 and switch 
to express non-fibrillar Col6a3 during differentiation.  
To validate these results in primary tissues from mice, we evaluated ECM 
expression in stratified adipose tissue stromal vascular fraction (SVF) cells. We isolated 
populations of eWAT SVF cells from age-matched ND and HFD-fed mice using a 
combination of centrifugation and magnetic bead cell sorting (Figure 3-2B).  This 
protocol allowed us to generate four fractions enriched for 1) mature adipocytes, 2) 
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CD31- CD45-  preadipocytes, 3) lineage positive (Lin+) CD45+ leukocytes, and 4) CD31+ 
endothelial cells.  In ND-fed animals, the preadipocyte-enriched fraction expressed the 
highest levels of Col1a1 at about a level ~20 fold higher than mature adipocytes (Figure 
3-2C). After HFD challenge, the preadipocyte-enriched fraction express Col1a1 at levels 
upwards of ~200X higher compared to mature adipocytes (Figure 3-2D). We also 
observed the induction of Col1a1 expression in leukocytes and endothelial cell fractions 
with HFD.  However, similar to ND tissues, the expression of Col1a1 in leukocytes and 
endothelial cells was only a fraction of the levels expressed by preadipocytes.   
We also examined Col6a3 and Lox expression in these samples.  In lean animals, 
the expression of Col6a3 is highest in the leukocytes compared to the mature adipocyte 
fraction (Figure 3-2E). After DIO however, there was an induction of Col6a3 in 
preadipocyte fraction and endothelial cells.  Preadipocytes had the highest expression of 
Col6a3 on a per cell basis.  Lox is primarily expressed by leukocytes in lean animals.  
With DIO, Lox expression was suppressed in leukocytes and induced in the preadipocyte 
enriched fraction (Figure 3-2F). These data may implicate the CD31- CD45-  
preadipocyte-enriched fraction as the major adipose tissue stromal component 
responsible for the induction of ECM and ECM regulatory genes with obesity and 
potential key contributors to ECM deposition during the progression of obesity. 
 
Microarray analysis demonstrates that preadipocytes are the major source of ECM gene 
expression in lean and obese adipose tissue 
To better understand the contributions of adipose tissue SVF cells to the pro-
fibrotic response to obesity, we used FACS to purify macrophages (CD45+ CD64+) and 
63	  	   	  
preadipocytes (CD31- CD45- Sca-1+ PDGFR α +) from eWAT and performed 
transcriptional microarray profiling (Figure 3-2G) (115) (216).  By enriching for PDGFR
α+ cells by flow cytometry, we have eliminated other possible mesenchymal cells (e.g. 
PDGFRα- pericytes that may have contaminated our previous CD31- CD45-  fractions 
(114, 115). In lean mice, we compared the expression profile of “resident” ATMs (CD45+ 
CD64+ CD11c-) and preadipocytes, the two most prominent SVF populations.  
Preadipocytes were significantly enriched for gene expression pathways involved in 
fibrinolysis, focal adhesion, ECM-receptor interactions, TGFß signaling, and integrin 
signaling (Figure 3-2H). Similar gene expression pathways were enriched in 
preadipocytes when we compared the gene expression profiles of CD11c+ ATMs and 
preadipocytes in HFD fed mice (data not shown).  This suggested that in both lean and 
obese settings, preadipocytes are the primary source of pro-fibrotic ECM gene 
expression.   
To evaluate the qualitative effects of HFD on preadipocytes, we compared the 
gene expression profiles of preadipocytes purified from ND and HFD fed animals.  This 
demonstrated a significant increase in gene pathways involved in ECM-receptor 
interactions, hematopoietic lineage, complement signaling, and cell adhesion components 
in preadipocytes from HFD fed mice (Figure 3-2I).  Decreases in gene pathways 
involved in amino acid metabolism and steroid biosynthesis were observed in HFD 
preadipocytes.  In summary, our microarray profiling further supports the role of 
preadipocytes as a major source of ECM component gene expression in lean and obese 
states and that DIO significantly activates the expression of ECM-receptor regulatory 
genes in preadipocytes.  
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Intracellular flow cytometry staining identifies collagen I+ (ColI+) preadipocytes  
In order to directly assess fibrillar collagen I production in adipose tissue stromal 
cells, we utilized intracellular flow cytometry with anti-collagen I antibodies, a method 
developed to identify fibrocytes in pulmonary fibrosis (175). ImageStream confocal 
imaging of 3T3-L1 preadipocytes in suspension identified punctate intracellular ColI+ 
staining vesicles that were independent of BODIPY+ lipid droplets (Figure 3-3A). Flow 
cytometry analysis of 3T3-L1 preadipocytes demonstrated positive ColI staining 
compared to isotype and secondary antibody-only controls (Figure 3-3B). 
Immunofluorescence visualization of immature pro-collagen I and mature collagen I 
revealed similar punctate staining patterns consistent with the active production of 
collagen protein in preadipocytes that matches gene expression profiling (Fig 3B). 
Primary preadipocytes isolated from mouse eWAT also reveal ColI+ cells using both flow 
cytometry and immunofluorescence detection methods (Figure 3-3C).  Overall, we 
validate the use of flow cytometry to delineate collagen I expressing preadipocytes.  
 
ColI+ preadipocytes are expanded with HFD in visceral but not subcutaneous depots 
Using our intracellular flow cytometry method, we set out to characterize collagen 
I expression in SVF cells in eWAT and iWAT with DIO. In both depots from ND and 
HFD-challenged animals, we observed ColI+ cells in the three major stromal vascular 
fraction cell populations: endothelial cells (CD31+), leukocytes (CD45+), and 
preadipocytes (CD31-CD45-Sca-1+, PDGFRα+). In eWAT, only about 10% of CD45+ 
leukocytes were ColI+ and these did not change with DIO in either eWAT or iWAT, 
making leukocytes unlikely to be a significant source of collagen production with DIO 
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(Figure 3-4A,B). A population of ColI + endothelial cells (CD31+ ColI +) was identified in 
both ND and HFD mice, which amounted to ~10% of the SVF population.   In eWAT the 
percentage of CD31+ ColI + decreased with DIO.  In contrast, the percent of PDGFRα+ 
ColI + preadipocytes rose from ~60% in the lean animal to ~90% in the HFD animals 
demonstrating a correlation between ColI + preadipocytes and fibrosis measures in eWAT 
with DIO. 
Next, we compared the percentage of ColI + cells as a percent of total SVF cells in 
the three major SVF populations in eWAT and iWAT. First, ColI + endothelial cells 
decrease from 7% to ~4% of the eWAT SVF with HFD, while in iWAT, ColI + 
endothelial cells increased significantly from 9% to 22% (p<0.0005) (Figure 3-4B).   No 
significant changes in ColI + leukocytes were observed in eWAT or iWAT with HFD.  In 
eWAT from lean mice, ColI + preadipocytes made up ~18% of the SVF.  This proportion 
significantly increased to ~32% with HFD.  In contrast, ColI + preadipocytes in the iWAT 
decrease with obesity. Representative eWAT and iWAT flow cytometry dot plots of 
preadipocyte populations are shown (Figure 3-4C.)  
Flow cytometry permitted a quantitative assessment of per-cell collagen I content 
by assessment of mean fluorescence intensity (MFI). Comparing the three populations, 
CD45+ cells were dimly stained (~750 MFI) compared to CD31+ endothelial cells and 
preadipocytes (~8000-14,000 MFI) (Figure 3-4D). After HFD, endothelial cell MFI 
decreased while preadipocyte MFI increased significantly. Collectively, our results 
demonstrate 1) an induction of ColI expression in eWAT preadipocytes with DIO, and 2) 
a quantitative increase of ColI+ preadipocytes with DIO.    
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Fat depot-specific differences in ColI + preadipocytes  
Next, we set out to further understand how the progression of obesity affects the 
quantity of collagen-expressing preadipocytes over time. Mice were fed a HFD for 10, 
20, and 30 weeks. In   eWAT, the percentage of ColI + cells significantly higher than age 
matched ND controls regardless the duration of HFD challenge (Figure 3-4E). Between 
10 and 20 weeks of HFD, the proportion of ColI + preadipocytes increases significantly in 
eWAT, but did not increase further after 20 weeks of HFD feeding.  At all time points, 
the content of ColI + preadipocytes in iWAT was less than in eWAT.  The proportion of 
ColI + preadipocytes in iWAT increases significantly at 10 weeks of HFD.  Surprisingly, 
we observed a decrease in these cells after 20 weeks of HFD relative to age matched ND 
controls due to an increase in these cells in lean mice between 10 and 20 weeks of age. 
After 30 weeks of HFD, no differences between ND and HFD were found between 
iWAT ColI + preadipocytes (Figure 3-4F).  
 
Adipose tissue secreted factors induce ECM expression in preadipocytes 
We next set out to examine if adipose tissue secreted factors were sufficient to 
modulate ECM expression in preadipocytes.  To address this, we designed an in vitro 
model where we collected conditioned media (CM) from eWAT and iWAT explants 
taken from ND and HFD-fed mice and then exposed 3T3-L1 preadipocytes to these 
media for 48 hours and followed with gene expression analysis.  Compared to media only 
controls, ND eWAT CM was sufficient to induce the expression of many ECM and 
fibrosis-related genes including Col4a1, Acta2, and Timp1 (Figure 3-5A).  ND iWAT 
CM-treated samples also induced Acta2 and Timp1 expression but not Col4a1.  HFD 
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eWAT CM induced Col4a1 to a similar degree as ND eWAT, however Col1a1, Col6a1, 
Col5a1, and Acta2 were induced by HFD eWAT CM to a greater extent than ND eWAT 
CM.  HFD iWAT CM did not induce Col1a1 expression and decreased expression of 
Acta2 and Timp1 relative to ND iWAT CM (Figure 3-5B). Flow cytometry MFI data 
further supported the ability of HFD eWAT CM can alone induce collagen I in these cells 
(Figure 3-5C). Together, findings are consistent with both our histology and flow 
cytometry data, suggesting that secreted factors derived from eWAT have a higher 
fibrogenic potential than those from iWAT.  
We hypothesized that inflammatory chemokines and cytokines uniquely secreted 
by HFD eWAT explants, but not HFD iWAT explants, could explain the induction of 
collagen I expression in preadipocytes.  To screen for potential factors, we performed a 
cytokine array analysis on the explant conditioned media to measure the relative amounts 
of 40 mouse cytokines secreted from similar weight adipose tissue explants from ND and 
HFD mice (Figure 3-5 D,E). Comparison of cytokines generated from ND and HFD 
mice revealed detectable expression of 22 cytokines above background in eWAT 
explants and 22 cytokines detected in iWAT.  Surprisingly, most cytokines were lower in 
HFD explants relative to ND explants.  IL-1 receptor antagonist (IL1RA) was one of the 
few cytokines identified as upregulated in eWAT and but not in iWAT as a potential pro-
fibrotic factor.  To test if IL1RA is sufficient to induce collagen production in 
preadipocytes, we treated 3T3-L1s with recombinant IL1RA. Flow cytometry analysis 
revealed that IL1RA was not sufficient to induce collagen expression. These data suggest 
that signaling mechanisms that regulate collagen expression in preadipocytes may not be 
chemokine-based.  
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TGFβ-1 as a potential signaling mechanism for pro-fibrotic preadipocyte activation  
We next set out to identify other putative pro-fibrotic factors secreted by HFD 
eWAT that might regulate expression of ECM components in preadipocytes. Our 
microarray data implicated TGFß signaling pathways in preadipocytes to fibrosis.  The 
source(s) of TGFß-1 in adipose tissue are not fully understood.  We first measured Tgfb1 
gene expression in total eWAT from lean and obese animals and observed a significant 
induction of Tgfb1 with DIO (Figure 3-6A). We then measured TGFβ-1 protein levels 
in conditioned media from eWAT explants from lean and obese animals. ELISA analysis 
reveals higher TGFβ-1 protein produced from HFD eWAT explants (Figure 3-6B), but 
not in iWAT explants (data not shown). To identify the primary regulated source of 
Tgfb1 in both lean and obese adipose tissue, we separated adipocytes and the stromal 
vascular fraction cells from eWAT by magnetic immunoaffinity isolation as in (Figure 3-
2B). We observed that both leukocytes and endothelial cells are major sources of Tgfb1 
regardless of diet, and the expression levels in both populations decreased with HFD 
(Figure 3-6C). To determine the contribution of ATM Tgfb1 expression, we performed 
gene expression analysis of FACS sorted ATMs (CD11b+F4/80+) and the non-ATM 
(CD11b-F4/80-) from eWAT SVF cells. Gene expression analysis revealed that ATMs 
express Tgfb1 at higher levels than non-ATMs in lean and obese mice (Figure 3-6D). 
Together, our data suggest that ATMs are a main source of Tgfb1 in eWAT.  
 
Alternatively activated macrophages induce collagen I in primary preadipocytes 
To understand how macrophage activation states influenced TGFß-1 expression, 
conditioned media from M0, M1, M2, and MMe macrophages were assessed for TGFß-1 
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production via ELISA (Figure 3-7A) (107).  M1 macrophages had decreased TGFß-1 
production compared to unstimulated M0. While M2 and MMe activation both 
significantly induced TGFß-1 compared to unpolarized M0 macrophages, the highest 
levels of TGFß-1 were secreted by M2 alternatively activated macrophages.   
Given these observations, we set out to investigate if TGFß-1 signaling was 
required for activating a pro-fibrotic preadipocyte phenotype. We exposed primary 
preadipocytes derived from mouse eWAT to macrophage-conditioned media (M0, M1, 
M2, MMe) with or without the TGFß-1 signaling inhibitor, SB431542 and measured 
collagen I protein expression by flow cytometry. CM from M2 macrophages was the 
strongest inducer of collagen I production (Figure 3-7B) compared to M0, M1 and MMe-
CM. The effect of M2-CM on collagen I induction was lost with the addition of the 
TGFß-1 signaling inhibitor SB431542.  This suggests that the potent effects of M2 
macrophages induced collagen I via a TGFß-1 receptor signaling pathway.   
Our data suggests that TGFß-1 as a macrophage derived signal that contributes to 
a pro-fibrotic phenotype in preadipocytes.  However, this is somewhat at odds with the 
decrease in Tgfb1 seen with HFD and the induction of pro-inflammatory M1/MMe 
activated CD11c+ ATMs with obesity.  We next considered the possibility that altered 
signals in resident CD11c- ATMs with obesity may be an underappreciated source of pro-
fibrotic signals. We compared gene expression profiles of resident CD11c- ATMs in 
eWAT from lean and obese animals (Figure 3-7C). Microarray analysis reveals elevated 
expression of gene pathways related to ECM-receptor interactions, focal adhesion, and 
lysosome pathway in resident macrophages from HFD mice. Overall, these data suggest 
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that resident ATMs from obese animals are unlike those of lean animals and are 
characterized by the induction of pro-fibrotic gene expression profile.   
 
Discussion 
 
Along with adipocyte hypertrophy, the progression from a lean to an obese state 
includes the dynamic reorganization of the adipose tissue ECM and takes the form of 
fibrosis with chronic obesity (203).  The progression to fibrosis in many tissue settings 
has been proposed to occur in four major phases: injury, activation of effector cells, 
dynamic deposition and crosslinking of ECM, and insufficient ECM resorption that 
promotes the accumulation of insoluble fibril-associated collagens (182). In this study, 
we have focused on understanding the sources of ECM production in adipose tissue with 
obesity and the mechanisms that contribute to phases 2-4 of the above paradigm in 
relation to obesity status and adipose tissue depots.   
Our findings shed light on the sources of ECM in adipose tissue, and highlight the 
differences in fibrotic potential between fat depots in mouse models of diet-induced 
obesity.  The increased density of the ECM in fibrotic adipose tissue increases the 
mechanical rigidity of the tissue and limits adipocyte function as an efficient nutrient 
store (202, 203).  Our data in a model of diet-induced obesity support this as we observed 
that adipose tissue hypertrophy in eWAT peaks in conjunction with an increase in fibrotic 
gene expression, ECM accumulation in adipose tissue, and an increase in the quantity and 
degree of expression of ColI in preadipocytes. iWAT lags behind eWAT in terms of 
ECM accumulation and ColI + preadipocyte accumulation suggesting tissue specific 
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regulation.  Our results are consistent with other studies (7), but provide stronger 
evidence that adipose tissue stromal cells contribute significantly to these changes.  
Our quantitation of hydroxyproline did not show a robust increase in collagen 
expression as did the picrosirius red histology staining and gene expression data. Few 
studies have used hydroxyproline quantitation in assessments of collagen content in 
adipose tissues; one study in particular performs an additional normalization step to 
account for this inconsistency (65). A possible explanation of why our hydroxyproline 
and histology/gene expression data is not aligned is due to the increase in lipid content in 
adipocytes that comes with obesity and may decreases total protein content in the input 
tissue substrate. Additionally, fibrosis develops heterogeneously in pericellular space; 
therefore averaging out hydroxyproline content per mg of tissue may obscure the 
findings.  
In obese mice and humans, gene expression of Col1a1 has been consistently 
reported, but the source of regulated expression of collagen I is unresolved (97, 214). 
Collagen I is a major insoluble fibril-forming component of the ECM in all tissues and is 
acutely induced by stimuli such as hypoxia and TGFß1 in fibroblasts (57, 65).  Groups 
have also reported PDGFRα signaling activation in promoting a pro-fibrotic mechanism 
and in blocking the adipogenic program in perivascular cells (86). Together, our data that 
further points to preadipocytes and their expression of fibril-forming collagen I is in 
agreement with published findings.  
We have employed methods to identify ColI + preadipocytes to establish that 
preadipocytes are a principal source of fibrillar collagen I.  While all major cellular 
populations in adipose tissue (mature adipocytes, endothelial cells, and leukocytes) 
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express ColI + to some degree, preadipocytes were the largest ColI + population in lean 
states and were the only ColI + population significantly induced with caloric excess. DIO 
also stimulated preadipocytes to increase their collagen I production on a per cell basis.  
Reflecting the increase in fibrosis in visceral depots, ColI + preadipocytes were enriched 
in eWAT compared to subcutaneous iWAT depots, but increased in both with HFD 
induced obesity. A potential limitation in intracellular flow cytometry is in the detecting 
of cells that may have ingested collagen such as seen in pulmonary fibrocytes (100). Our 
data suggests that the detection of pro-collagen I in preadipocytes along with the gene 
expression profiling from FACS sorted cells make this possibility unlikely for 
preadipocytes.  An additional caveat is that we based our observations of collagen 
expression on an immature form of collagen, which does not necessarily reflect the true 
nature of fibrotic collagen that has undergone the post-translational modifications and 
crosslinking to render it insoluble.  
Total collagen content measured by complementary methods indicated that at per 
milligram of tissue, iWAT from lean animals contains more collagen I than in eWAT.  
HFD induced collagen accumulation and a fibrotic profile in eWAT but not in iWAT. 
Uniquely, our data reveal that after HFD, the largest population of ColI + cells in iWAT 
are CD31+ endothelial cells and not preadipocytes as we observed in eWAT.  This 
suggests that a major differentiator between eWAT and iWAT in the control of fibrosis 
may be the capacity to degrade fibrillar collagen.  This may vary with duration of HFD 
stimulation as we observed that Col1a1 gene expression was not substantially induced 
until after 8 weeks of HFD.  This correlated with the observation of lower adipose tissue 
collagen content in eWAT with shorter (6-8 weeks) HFD exposure.  These data 
73	  	   	  
altogether further reveal differences in adipose tissue depot fibrogenic potential, chronic 
inflammation, and influence on metabolism.  
Conditioned media from eWAT or iWAT explants revealed that eWAT, but not 
iWAT, induced Col1a1 expression in 3T3-L1 preadipocytes. Cytokine arrays identified 
IL-1RA a candidate that was induced in eWAT but not iWAT with HFD, however this 
cytokine was not sufficient to induce Col1a1.  This led us to consider other secreted 
molecules as possible mediators of preadipocyte fibrosis such as TGFß-1. TGFß-1 plays 
a complex role in metabolism in that it plays numerous functions in development, 
growth, and wound repair (208). TGFß-1 is implicated in ECM remodeling, as it can 
inhibit matrix metalloproteinase ECM degradation activity, which could further promote 
ECM accumulation (167).  At the physiological level, TGFß-1 plays a regulatory role in 
insulin transcription, and blocking TGFß-1 signaling can protect against obesity-induced 
insulin resistance (236). TGFß-1 can inhibit adipogenesis via a Wnt-independent, Smad3-
mediated pathway in preadipocytes (37, 38, 215).  
TGFß and associated signaling pathways have in the past been investigated in 
human preadipocytes, however we believe this study produced insufficient results in a 
study of only a single fibrosis marker (24). Our current study further implicates TGFß-1 
in fibrosis as we investigate its role in the expression of synthesized intracellular fibril-
forming collagen type I.  
Inflammation is also associated with fibrosis in pre-clinical studies and is 
essential for adipose tissue expansion and remodeling (232).  ATM depletion or 
inactivation attenuates fibrosis (221). In our studies, we observed higher levels of Tgfb1 
gene expression in tissues from obese animals and that ATMs are a main source of Tgfb1. 
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Our gene expression data suggests that the increase of Tgfb1 expression in whole tissue is 
most likely due to a quantitative increase in ATM content and not in per cell expression 
with obesity.  We replicated macrophage activation states normally present in lean and 
obese animals using an in vitro model in order to investigate how ATM activation 
influenced preadipocyte ECM expression. Previous studies have only evaluated quiescent 
or M1 activated macrophage signaling to preadipocytes (96). Despite the association 
between CD11c+ ATM accumulation with obesity and fibrosis, we observed that M1 and 
MMe polarized bone marrow-derived macrophages did not induce significant collagen 
protein expression in preadipocytes compared to M2 macrophage conditioned media. 
This agrees with other reports that implicate M2 macrophages in ECM remodeling via 
TGFß-1 to promote ECM accumulation (167, 198). Potential approaches to support this 
model include generating mice with macrophage-specific deletion of TGFß-1.  
Together, we propose a model where after dietary challenge, resident “M2” 
ATMs, but not pro-inflammatory “M1” or metabolically activated “MMe” ATMs, 
promote a pro-fibrotic phenotype in preadipocytes.  In support of this, our microarray 
studies demonstrate significant activation of ECM-receptor pathways in resident ATMs 
between lean and obese mice.   
In summary, our observations reveal that preadipocytes are major producers of 
fibrillar type I collagen. Because adipose tissue fibrosis in the pathological sense has few 
explicit criteria, it still remains unclear at what threshold point or at what scale the 
increased fibrotic deposition begins to have negative effects on metabolism. In addition, 
there remain significant gaps between our understanding of adipose tissue ECM 
remodeling in clinical and pre-clinical models.  In mice, the link between fibrosis, 
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macrophage inflammation, and insulin resistance is fairly uniform.  In clinical 
populations, the relationship between fibrosis and metabolic disease is more complex in 
line with variation between the relationship between obesity and metabolic health (1, 54, 
105, 108, 203).  Our studies suggest that the function and pro-fibrotic state of 
preadipocytes may contribute to this variation and may be a future direction of research 
to unravel this problem.  
 
  
76	  	   	  
 
 
Figure 3-1. Obesity increases ECM density in visceral adipose tissue depots. 
(A) Body weight, and eWAT and iWAT fat pad weights (B-C) were measured from ND 
and HFD mice challenged 4, 8, 12, 16, 20, or 24 weeks of HFD. (D) Picrosirius red 
histological stains from ND/HFD eWAT and iWAT tissues at 12 weeks and 24 weeks of 
diet, with quantification of %Col+ staining area at 24 weeks of HFD (scale bar = 200μ
M). (E) Total eWAT collagen content shown from time course HFD, ND sample is from 
adult mouse at 16 weeks of age. (F) Total collagen content shown from iWAT tissue of 
ND or 16 weeks HFD diet. (G) Gene expression analysis of eWAT and iWAT at 4, 8, or 
16 weeks of HFD, each time point is represented as fold change over age-matched ND 
controls. Samples represented as fold change over age-matched lean controls. (mean ± 
SEM; n=4 per group for all graphs, *p<0.05, **<0.01***0.001, ****0.0001)  
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Figure 3-2. Preadipocytes are major source of collagen type I in adipose tissue.  
(A) Time course 3T3-L1 preadipocyte cell line differentiation and gene expression 
analysis, all data points normalized to Day 0 time point. (B) Magnetic microbead cell 
fractionation strategy is shown. (C-F) Gene expression analysis on sorted populations 
from eWAT, from ND and 16wk HFD age-matched animals. All data normalized to 
internal adipocyte fraction values.  (mean ± SEM; n=4 per group for all graphs, *p<0.05, 
**<0.01***0.001, ****0.0001)  
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Figure 3-2 continued.  
(G) Gating strategy for preadipocytes is shown (CD31-CD45-Sca-1+PDGFRa+). (H-I) A 
visual representation of microarray analysis data showing fold change of gene expression 
cluster families (mean ± SEM; n=3-4 per group, *p<0.05, **<0.01***0.001, ****0.0001)  
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Figure 3-3. Validation of collagen type I detection in preadipocytes. (A) Image 
Stream cytometer visualization of 3T3-L1 cells in suspension stained with lipid stain 
(BODIPY) in green and Col 1 in red. (B) Intracellular Collagen I flow cytometry staining 
controls, immunofluorescence pro-collagen I and mature collagen I stains (green), and 
actin cytoskeleton (red) are shown on 3T3-L1 cells. (C) Primary mouse preadipocyte 
flow cytometry and immunofluorescence stains are shown (scale bar = 100μM).  
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Figure 3-4. ColI + preadipocytes are induced in visceral adipose tissue depots with 
diet-induced obesity. (A) Flow cytometry stains reveal Collagen expression in major 
adipose tissue stromal populations in ND and HFD eWAT. (B) Populations of ColI + 
populations were examined in eWAT and iWAT after 16 weeks of HFD challenge. (C) 
Representative dot plots of preadipocyte populations and Collagen I expression from 
eWAT and iWAT from ND and HFD-fed animals. (D) Median fluorescence intensity 
(MFI) of Collagen I stain is shown. (E-F) Populations of gated CD31-CD45- ColI + 
preadipocytes from eWAT and iWAT are shown at 10, 20, and 30 weeks of HFD 
challenge (mean ± SEM; n=4 per group, *p<0.05, **<0.01***0.001, ****0.0001).  
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Figure 3-5. Obesity-associated factors from visceral adipose tissue explants induce 
collagen type I expression in preadipocytes. (A-B) Gene expression analysis of fibrosis 
markers from 3T3-L1 preadipocyte cells exposed to eWAT or iWAT explant conditioned 
media. (C) Collagen I MFI from 3T3-L1s exposed to ND and HFD eWAT explant 
conditioned media. (D-E) Cytokine array blots are shown from eWAT and iWAT explant 
conditioned media. (40wks HFD with ND age-matched lean controls). (F) Intracellular 
Collagen I MFI flow cytometry stain from 3T3-L1s treated with cytokines. (mean ± 
SEM; n=24 per group, *p<0.05, **<0.01***0.001, ****0.0001)  
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Figure 3-6. Adipose tissue macrophage-derived TGFβ-1 is induced with obesity  
(A) Gene expression of Tgfb1 in eWAT after 20 weeks of HFD. (B) ELISA quantitation 
of TGFβ-1 protein levels in eWAT conditioned media. (C) Gene expression of Tgfb1 in 
microbead-sorted stromal populations. (D) Gene expression analysis on FACS-sorted 
ATMs and Non-ATMs shown from ND or 16 week HFD-fed animals. (mean ± SEM; 
n=3-4 per group for all graphs, *p<0.05, **<0.01***0.001, ****0.0001)  
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Figure 3-7. Alternatively activated macrophage-derived factors induce collagen type 
I expression in preadipocytes via TGFß signaling. (A) Quantified TGFβ-1 levels 
secreted from activated macrophages (B) Collagen I MFI from primary mouse 
preadipocytes treated with activated macrophage conditioned media and TGFβ -1 
signaling inhibitor. (C) Gene family fold change increase comparing resident 
macrophages from lean and obese eWAT. (mean ± SEM; n=3-4 per group, *p<0.05, 
**<0.01***0.001, ****0.0001).  
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Chapter 4 
 
Adipose Tissue Fibrosis After Weight Loss is Related to  
Retention of Pro-fibrotic Preadipocytes  
 
Abstract  
 
Obesity alters the architecture of the ECM and is associated with excessive ECM 
accumulation in the form of adipose tissue fibrosis. Weight loss can improve metabolism 
and decrease adipose tissue inflammation, however in many cases, the risk of 
cardiovascular and metabolic disease remains high in formally obese individuals. The 
reasons for this are unclear, but one potential mechanism is that obesity induces 
permanent changes in adipose tissue function that do not resolve with weight loss.  This 
hypothesis is supported by reports that suggest that adipose tissue fibrosis is sustained in 
in patients after bariatric surgery induced weight loss. To examine the mechanisms 
behind this effect, we have utilized an animal model of weight loss to investigate how the 
ECM is reorganized with loss of fat mass. We observed that ECM accumulation increases 
dramatically after weight loss, and that insulin sensitivity remains abnormal despite 
normalization in body weight by removal of high fat diet feeding.  Endothelial cells and 
preadipocytes are major sources of ECM components type I collagen and elastin.  ColI+ 
preadipocyte content increases in gonadal fat pads and remain elevated in quantity with 
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weight loss. In contrast, the quantity of ColI+ preadipocytes return to normal levels in 
subcutaneous adipose tissue with weight loss.  The per cell expression of ColI and Elastin 
are decreased with weight loss, suggesting that the signals inducing ECM production are 
dampened.  Gene expression analysis supported a general decrease in pro-fibrotic gene 
expression in eWAT with weight loss.  Candidate cytokines were identified by protein 
array, and were found to be associated with restoration of a low fibrotic environment with 
weight loss.  These data suggest that the sustained presence of adipose tissue fibrosis 
after weight loss in eWAT does not relate to a sustained high level of ECM production 
and may relate to a decrease in ECM degradation machinery. Our findings have 
implications to sustained impairment in adipose tissue function after weight loss.   
 
Introduction  
 
The ECM in adipose tissue plays an important role in the regulation of 
adipogenesis, adipocyte function, and adipose tissue architecture (39, 44). Adipose tissue 
expansion requires orchestrated interplay between numerous cell types (177, 186, 200). 
With the development of obesity, an increase in ECM density is widely observed which 
is hypothesized to reduce structural plasticity of adipose tissue and contributing to 
metabolic dysfunction (53, 74). This plasticity is integral to metabolic function of adipose 
tissues, as the inability to remodel the ECM is correlated with aberrant insulin sensitivity 
and metabolic disease (53, 197, 202). However, some studies suggest fibrosis may have a 
protective effect on metabolism by restricting adipocyte hypertrophy (9, 10, 203). Given 
the importance of healthy adipose tissue expansion and contraction in metabolic health 
86	  	   	  
we are interested in understanding how the adipose tissue ECM is remodeled in different 
nutrient settings. Understanding how adipose tissue is ECM remodeling in weight loss in 
particular is of high priority given the common problem of substantial weight regain after 
initial weight loss (WL) interventions.  Understanding the long-term changes obesity has 
on adipose tissue may also aid in the understanding why the risk of cardiovascular 
disease does not diminish despite the resolution of obesity (177, 237).  
 During WL, the ECM undergoes massive reorganizations in architecture in 
response to a rapid decrease in adipocyte size and quantitative change in stromal cell 
populations (29, 106). Evidence suggests that adipose tissue function and architecture do 
not return to normal in patients that have undergone bariatric surgery, which may be due 
to a permanent disruption of ECM architecture generated by chronic obesity (53, 54). 
Studies have shown that diabetic patients have stiffer and more fibrotic subcutaneous 
adipose tissues and lose less weight after bariatric surgeries, providing further support for 
the ECM flexibility-metabolism paradigm (1, 174). One of the most striking observations 
is that ECM accumulation appears to persist even in obese patients that have undergone 
WL (53, 54, 135). Gene expression studies of humans that have undergone bariatric 
surgery reveal altered expression of ECM components after WL (53). Data that integrate 
both metabolic and histological studies from clinical and pre-clinical models are limited 
as few, if any, studies have investigated effects of WL in a longitudinal manner (1).   
The persistence of inflammation adipose tissue after is hypothesized to be a major 
contributor to ECM deposition, and several studies have supported a link between the two 
processes (54, 186, 199). Adipose tissue from subcutaneous regions of formally obese 
patients have an inflammatory profile more similar to obese patients (29). There have 
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also been conflicting studies reporting that metabolic perturbations remain in formally 
obese mice as well as humans (3, 44). Animal models of short-term weight-loss reveal 
the recruitment of ATMs, which appears to have functions in initiating ECM remodeling 
and in the metabolism of excess lipids (54, 106, 110, 231). In human models of surgery-
induced WL, there is a decrease of inflammatory ATM activation and an overall decrease 
of ATMs (29, 44).  
There are three major gaps in knowledge of how WL alters the adipose tissue 
ECM. First, the cellular components in adipose tissue that produce ECM materials with 
weight loss have yet to be fully delineated. Second, the connections between the 
qualitative and quantitative changes in stromal populations, and the increase in ECM 
accumulation that is observed after WL are not understood. Third, mechanisms of cell-
cell and cell-matrix communications that influence ECM component production are also 
not well understood.  Filling these gaps in knowledge has the potential to identify 
modifiable pathways to either amplify weight loss responses or potentiate to increase 
resolution of adipose tissue inflammation in the weight-reduced state.   
In this work, we fill in these gaps with an investigation that integrates metabolic 
data with in-depth observations of histological findings and investigations into changes in 
adipose tissue stromal cells with WL relating to ECM production. Our animal model 
studies reveal that, along with the inability for insulin sensitivity to normalize after WL, 
the ECM becomes denser after WL.  While the quantitative increase in preadipocytes 
induced by HFD are sustained after prolonged weight loss, the per cell expression of 
ECM proteins such as collagen and elastin are decreased.  This suggests that the 
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sustained level of adipose tissue fibrosis seen after weight loss is not due to ongoing 
activation of ECM production.   
 
Materials and Methods 
 
Animal Studies 
C57BL/6J Male mice were fed ad libitum normal diet (4.5% calories from fat; 
PMI Nutrition International) or high fat diet (60% calories from fat; Research Diets) 
starting at 6 weeks of age for durations as described.  WL was induced by replacing high 
fat diet, with ad libitum normal diet for duration described. Glucose tolerance tests (GTT) 
and insulin tolerance tests (ITT) were performed after a 6-hour fast. For GTT, mice were 
injected IP with D-glucose (0.7 g/kg). For ITT, mice were injected IP with human insulin 
(1 unit/kg). For both GTT and ITT, blood glucose concentrations (mg/dl) were measured 
0, 15, 30, 45, 60, 90, and 120 min after injection. Animal procedures were approved by 
the University Committee on Use and Care of Animals at the University of Michigan and 
were conducted in compliance with the Institute of Laboratory Animal Research Guide 
for the Care and Use of Laboratory Animals.  
 
Total collagen assessment 
Total collagen staining was performed on formalin-fixed paraffin-embedded 
tissue sections using the Picrosirus Red Stain Kit (Polysciences, Inc. Warrington, PA) or 
by Masson’s Trichrome stain performed by the Tissue Core of the University of 
Michigan Comprehensive Cancer Center. Images were captured using an Olympus 
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inverted microscope fitted with an Olympus DP27 camera. Image J software (NIH) was 
used to measure density. Hydroxyproline content was measured using the 
Hydroxyproline assay kit from QuickZyme Biosciences (Leiden, Netherlands, dist. 
Cedarlane Labs Burlington, NC).  
 
Flow Cytometry  
Adipose tissues were dissociated as previously described (36). For intracellular 
collagen staining, cells were incubated in Fc Block then stained with surface antibodies 
(Affymetrix eBioscience, San Diego, CA) and Live/Dead viability stain (Thermo Fisher 
Scientific-Life Technologies, Carlsbad, CA) for leukocytes (Live/Dead-CD64+, CD45+) 
preadipocytes (Live/Dead-CD31-CD45-Sca-1+, PDGFRα+) and endothelial cells (CD31+) 
for 45 min at 4°C. Briefly, intracellular stains were performed using FOXP3 Fix/Perm 
buffer (BioLegend, San Diego, CA) followed by 15 min block with 0.5% goat serum, a 
1hr incubation with 0.5μg of rabbit Collagen Type I antibody (Rockland, Limerick, PA) 
or a-Elastin antibody (abcam, Cambridge, UK), three washes, and 30 min incubation with 
0.2μg of goat anti-rabbit AlexaFluor 647 antibody (Thermo Fisher Scientific-Life 
Technologies, Carlsbad, CA). Flow cytometry performed on FACSCanto II Flow 
Cytometer or BD Accuri C6 (BD Biosciences, San Jose, CA.) and analyzed with FlowJo 
data analysis software (Ashland, OR).  
 
Explant tissue culture and conditioned media  
Tissue explants were cut to 150mg pieces and cultured in serum-free AIM-V 
AlbuMAX (BSA) media for 48 hours at 37°C (Thermo Scientific-Life Technologies 
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Carlsbad, CA). For ELISA and Cytokine Array, tissues were cultured in serum-free 
DMEM with antibiotics for 48 hours 37°C. Explant conditioned media was pooled and 
assessed with the Proteome Profiler Cytokine Array (Panel A) (R&D systems, 
Minneapolis, MN). Immunoblots were quantified after black/white equilibration for 
integrated pixel density with ImageJ.  Secreted TGFβ-1 protein from tissue explants 
were measured with ELISA at the University of Michigan Cancer Center Immunology 
core facility. 
 
Gene expression analysis 
Total RNA was extracted using RNeasy Mini Kits (QIAGEN), and cDNA was 
generated from 0.5ug of RNA using high-capacity cDNA reverse transcription kits 
(Applied Biosystems). Power SYBR Green PCR Master Mix (Applied Biosystems) and 
the StepOnePlus System (Applied Biosystems) were used for real-time quantitative PCR. 
Arbp expression was used as an internal control for data normalization. Samples were 
assayed in duplicate, and relative expression was determined using the 2−ΔΔCT method.  
 
Statistical Analysis 
Data are shown as mean ± standard error of the mean (SEM). Differences 
between groups were determined using two-tailed Student t test analysis with GraphPad 
Prism 6.0e software. p < 0.05 was considered significant.  
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Results 
 
Extracellular matrix deposition in adipose tissue is not removed after short-term weight 
loss 
While there are various published models of WL in mice and humans, few include 
observations of tissue sizes, metabolism, and analyses of ECM architecture after WL in 
both major visceral and subcutaneous fat pads. We performed a short time course WL 
analysis of obese HFD fed C57/BL6 male mice induced to lose weight by replacing the 
HFD with ND for 2 weeks. First, body weights decreased in the 2 week WL group 
(Figure 4-1A). Fasting glucose and insulin levels show significant improvement within 
two weeks of WL compared to HFD fed control mice. The weights of epididymal 
(eWAT) and subcutaneous inguinal (iWAT) adipose tissue depots increased significantly 
in the HFD group and decreased after the diet was switched, but did not return to normal 
diet weights after two weeks of WL (Figure 4-1B). We explored adipose tissue ECM 
architecture of eWAT via Trichrome Collagen stain, and Verhoeff van Gieson’s Elastin 
stain, where we observed an increase in ECM density after HFD.  WL did not result in 
any significant changes in collagen or elastin material staining in eWAT with this short 
term WL paradigm.   
 
Weight loss increases density of the ECM 
The above result suggests that longer WL intervention may be required to return 
adipose tissue to a normal ECM architecture.  To examine this we used a longer term WL 
paradigm by examining age-matched lean animals (ND, 20 weeks), obese animals (HFD, 
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20wks), and a set of weight loss animals (WL) that was placed on HFD for 12 weeks, 
followed by 8 weeks of calorie restriction via feeding of ND chow. Body and tissue 
weight measurements reveal an increase in weights with HFD, and subsequent decrease 
in weight with WL (Figure 4-2A). Metabolic assessments revealed that glucose tolerance 
normalizes after 8 weeks of WL, however insulin tolerance tests reveal that animals are 
less insulin sensitive (Figure 4-2B) compared to age matched ND mice.   
Histological observations of adipose of eWAT tissues via Picrosirius total 
collagen stain revealed an increase in ECM accumulation and adipocyte hypertrophy 
after HFD as previously observed. After 8 weeks of WL, there was a significant 
qualitative increase in the accumulation of collagen based on Picrosirius red staining 
(Figure 4-2C). We assessed collagen content by hydroxyproline quantitation from 
eWAT samples. No significant changes in hydroxyproline were noted between ND and 
HFD groups, however WL led to a significant increase in eWAT hydroxyproline content 
which is in agreement with histological findings (Figure 4-2D). There was a statistically 
significant difference between groups as determined by one-way ANOVA (F, (2, 25) = 
8.060, p=0.002) and Kruska-Wallis test shows a significant difference between diet 
(p=0.0036). 
 
Collagen I+ adipose tissue stromal cells increase after weight loss 
Next, we set out to investigate the cellular changes in adipose tissue stromal cells 
that may account for the increased ECM deposition and gene expression changes 
observed after WL. In the previous chapter, we identified three distinct stromal cell types 
that express fibrillar type 1 collagen (ColI).  Endothelial cells and preadipocytes were the 
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most active collagen-expressing populations; therefore we hypothesized that these 
populations may be responsible for the excess ECM deposition observed after WL.  
We measured the prevalence and expression levels of two prevalent ECM 
components, Collagen I and Elastin, in endothelial and preadipocyte populations. Mice 
were fed either a ND (20 weeks), HFD (20 weeks), or put through a WL regimen (12 
weeks HFD followed by 8 weeks ND). Quantitation of endothelial cell (CD31+) and 
preadipocyte (CD31-CD45-Sca1+PDGFRa+, PreAds) populations was performed with 
flow cytometry.  As a percentage of the SVF, eWAT endothelial cells did not change 
with HFD or WL (Figure 4-2E).  PreAds (%SVF) increase with HFD and remain 
elevated with WL. Two-way ANOVA (ordinary) reveals significant effect of diet (F (2, 
18) =20.32, p<0.0001), and Tukey’s multiple comparison test reveals significant 
differences between ND vs. HFD and ND vs. WL (p<0.05). Normalization to adipose 
tissue weight (cell/g) demonstrates that WL increases the overall density of endothelial 
cells and PreAds in eWAT relative to both ND and HFD fed controls.  iWAT had a 
different pattern.  As a percentage of SVF, iWAT endothelial cells and PreAds increase 
with HFD and return to levels similar to ND with WL (Figure 4-2F).  Normalized to 
adipose tissue weight, there was a significant increase in iWAT endothelial cells with WL 
similar to eWAT.  No significant differences were seen in the density of PreAds with 
HFD or WL.  This demonstrates depot specific differences in stromal cell remodeling 
with WL. Accumulation of PreAds in eWAT increases with WL while in iWAT, preAds 
change their number in proportion to fat mass with WL.   
In the previous chapter, we discussed and validated the use of a technique to 
quantitate intracellular fibrillar type 1 collagen producing cells. We applied this technique 
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to investigate how weight gain and loss affects the number of cells that produce collagen 
I and to examine the expression levels of collagen at a per cell basis. A representative 
flow cytometry plot is shown of eWAT and iWAT preadipocytes gated as a percent of 
CD31-CD45-Sca1+ cells (Figure 4-3 A,B).  
In eWAT, the percent of ColI + endothelial cells in the SVF decreases with 
obesity, and returns to levels similar to ND mice with WL (Figure 4-3C). The quantity of 
ColI + PreAds increased significantly with HFD and demonstrated a small but significant 
further increase with WL.  When normalized to fat pad weight, WL increased the density 
(cells/gram of adipose tissue) of both endothelial cells and PreAds compared to both ND 
and HFD conditions (Figure 4-3D). In iWAT, ColI + endothelial and PreAds increased 
significantly with HFD, then decreased dramatically after WL to return to levels similar 
to ND mice (Figure 4-3E). When normalized to iWAT mass, no significant differences 
in the density of collagen expressing cells in the iWAT between the ND, HFD or WL 
groups (Figure 4-3F).   
We next evaluated per cell expression of ColI by median fluorescence intensity 
(MFI).  HFD decreased collagen I expression in endothelial cells, and did not increase 
with WL in eWAT (Figure 4-3G). In eWAT PreAds increased collagen expression with 
HFD, and this decreased after WL to a level below what was observed in lean mice. In 
iWAT, an increase in collagen expression was only observed in endothelial cells after 
WL (Figure 4-3H).  Overall this demonstrates that per cell expression of ColI in eWAT 
PreAds is decreased WL although their content in remains high.  This also demonstrates 
depot specific differences in the capacity of stromal cells to alter their quantity with WL 
– a more robust capacity to return endothelial cell and PreAd levels to normal in iWAT.   
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Elastin1+ adipose tissue stromal cells increase after weight loss 
Another prevalent ECM component relatively unexplored in adipose tissue is 
elastin. We applied a similar strategy as our intracellular collagen I stain to measure 
production of alpha elastin in endothelial and PreAds populations. Control staining 
demonstrated specificity of our elastin flow cytometry experimental controls (Figure 4-
4A). Analysis of SVF cells revealed that the majority of PDGFRi+ PreAds express elastin 
in both eWAT (~90%) and iWAT (~75%) of  CD31-CD45-Sca1+ cells (Figure 4-4B).  
In eWAT from ND mice, ~10% of endothelial cells expressed elastin (Eln+) and 
~20% of the PreAds were Eln+ (Figure 4-4C).  HFD did not alter the quantity of Eln+ 
endothelial cells but the quantity of Eln+ PreAds doubled.  This increase in Eln+ PreAds 
was sustained after WL in eWAT. Normalizing to fat pad weight (Eln+ cells/g), there are 
no significant changes in Eln+ endothelial cells or PreAds with HFD in eWAT.  WL 
induces a significant increase in Eln+ cells in both populations in eWAT.  
In iWAT, HFD significantly increased the quantity of Eln+ endothelial and 
PreAds as a %SVF.  WL induced a similar decrease in Eln+ cells to levels similar to lean 
mice (Figure 4-4D). Normalizing to fat pad weight, the density of Eln+ endothelial cells 
increased after WL and no significant differences were seen in Eln+ PreAds between 
groups. Examining elastin MFI, endothelial cells express elastin at higher levels than 
PreAds in eWAT but not iWAT (Figure 4-4E).  In both depots, elastin MFI increases 
with HFD and decreases after WL for both endothelial cells and PreAds.  
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Weight loss decreases gene expression of ECM components and markers of fibrosis 
To assess global changes in ECM components and regulatory genes at the tissue 
level, we analyzed gene expression in whole eWAT samples from ND, HFD, and WL 
mice. HFD induced expression of Col1a1 and Col6a3 (Figure 4-5A). Markers of fibrosis 
such as Spp1, Postn, and Tgfb1 were also induced, however only Spp1 reached statistical 
significance (Figure 4-5B). Increases in expression of tissue inhibitor of matrix 
metalloproteinase family genes (TIMPs) are consistent with the generation of a pro-
fibrotic environment with HFD and a downregulation of ECM degrading enzymes 
(Figure 4-5C). A decrease in the levels of Mmp2 and Mmp9 after both HFD and WL 
suggests a decrease in the degradation of the basement matrix. An increase of Mmp12 
and Mmp14 and subsequent decrease after WL suggest active ECM degradation was 
promoted. We also measured the makers of brown/beige adipocytes and noted few 
changes in Pgc1a and a strong induction of Ucp1 after HFD.  Ucp1 decreased after WL, 
but was elevated compared to ND lean animals (Figure 4-5D). Overall, gene expression 
analyses reveal that WL decreases gene expression of ECM remodeling factors in eWAT.  
This suggests that the increase in collagen staining in WL mice indicates persistent of 
previously deposited ECM components and not the ongoing generation of a pro-fibrotic 
environment.   
 
Secreted factors from weight loss tissues identify weight-dependent cytokine and growth 
factor changes 
 To screen for cytokines that change with weight loss that may relate to a sustained 
pro-fibrotic setting, we performed a cytokine protein array screen for 40 cytokines on 
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conditioned media from ND, HFD, and WL explants (Figure 4-6A). 20 cytokines were 
detected above background. The cytokines elevated in HFD and WL samples but not in 
ND samples were IL-1 receptor antagonist (IL-1RA) and, monocyte chemotactic protein 
5 (MCP-5, also known as CCL12) (Figure 4-6B).  Cytokines that were restored to the 
level of ND mice were MIP1A, RANTES, and TNFα.  
 The cytokine array does not measure growth factors previously implicated in 
fibrosis such as TGFβ-1. Therefore, we assessed levels of total TGFβ-1 in eWAT ND, 
HFD, and WL explant conditioned media. ELISA results suggested TGFβ-1 levels are 
elevated in HFD and WL conditioned media, however only the levels in the WL samples 
reached significance (Figure 4-6C).  This suggests that sustained TGFß-1 may contribute 
to sustaining a pro-fibrotic environment in eWAT with weight loss.  Lastly, to assess if 
TGFß-1 signaling is sufficient to induce expression of ECM components, we added 
recombinant TGFß-1 to the 3T3-L1 preadipocyte cell line. TGFß-1 significantly induced 
gene expression of Cola1, Col6a3, and Spp1 (Figure 4-6D).  
 
Discussion 
 
In the current study, we sought to understand why metabolic perturbations remain in 
formally obese patients. To investigate these observations, we focused our attentions to 
filling in gaps in the published literature by evaluating the dynamics and reorganization 
of adipose tissue ECM architecture after WL.  Overall, our findings demonstrate in 
mouse models of WL, that normalization of fat pad weights does not revert the adipose 
tissue ECM to its pre-obese status. Our most surprising finding was that an increase of 
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fibrotic ECM accumulation is observed after an 8 weeks WL intervention that normalized 
body and tissue weight.  This is most prominently seen in the eWAT and not in iWAT. 
We have validated this finding via multiple and complementary analyses such as by 
histological methods (Picrosirius, Verhoeff’s, Trichrome) and by biochemical methods 
(total tissue hydroxyproline). This may be due to the dynamic ability of eWAT to adapt 
expand in response to metabolic demand.  
 We focused on investigating the mechanisms by which ECM accumulation is 
sustained or increased with WL. The quantity of ColI + and Eln+ stromal cells increase 
dramatically in eWAT after WL, and that the main producers of these compounds are 
endothelial cells and PreAds.  Despite this increase in cell quantity, both endothelial cells 
and PreAds decreased per cell expression of these components after WL. Gene 
expression analysis supports this observation as gene expression of ECM components 
decrease in whole eWAT adipose tissue samples with WL.   
Overall, our data is consistent with the model that the increased quantity of pro-
fibrotic PreAds induced by HFD in eWAT remain after WL and retain pro-fibrotic 
characteristics (ColI and Eln production). However these characteristics are dampened 
relative to the HFD situation.  The persistence of adipose tissue ECM is likely due to a 
combination of persistent pro-fibrotic PreAds population and an inability of the ECM 
degradation machinery to remodel the adipose tissue fibrosis back to a normal state. 
Subsequently, we have not analyzed ECM degradation capacity with WL. It is possible 
that suppression of ECM degradation is more important than the induction of new ECM 
production.     
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Since endothelial cells are such a small population of the SVF (~10%) it is 
unlikely this population plays a significant causative role in the pathogenesis of fibrosis. 
Our data align with other reports implicating PreAds as as pro-fibrotic cells under 
inflammatory conditions, however we have taken further steps in providing data showing 
that these cells can also produce ECM components (74, 96). Elastin is an ECM 
component that remains understudied, and to our knowledge, our work is one of the few 
that explores the elastin matrix in adipose tissues (5, 14). Our analysis revealed that 
populations and production of elastin increases in PreAds with diet-induced obesity, and 
much like collagen, expression of elastin also decreases after weight loss.    
 We observed significant adipose tissue depot specific changes after WL.  For 
most of our stromal measures (e.g. quantity of Col1+ PreAds), the effects of HFD were 
not readily reversible in eWAT and were reversible in iWAT. This was apparent in 
similar content of iWAT stromal cells when normalized to adipose tissue weight. This 
suggests that iWAT depots have a more robust capacity to dynamically decrease the 
stromal cell induction as seen with HFD. It may also relate to the pro-fibrotic changes 
induced primarily in the eWAT that may limit the ability of PreAds to return to levels 
similar to a lean state. We postulate that the decrease in PreAd content in iWAT is due to 
an exhaustion of the PreAd pool, which may not be the case in eWAT.    
Adipose tissues are rich with a variety of ECM compounds, such as fibrillar and 
non-fibrillar collagens, fibronectins, laminins, and proteoglycans. A limitation in our 
study is that we did not explore how these additional components are deposited or 
degraded. An important next step in the evaluation of ECM architecture in the context of 
fibrosis is the analyses of crosslinking enzymes such as Lysyl oxidase and 
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Transglutaminase, and matrix assembly elements (Decorin, Periostin,) that function to 
reinforce ECM rigidity. We postulate that higher degrees of ECM crosslinking may result 
in the inability of enzymes to degrade and remodel the architecture. Along with this, 
further investigation of the activities of degradation enzymes like Matrix 
metalloproteinases (MMPs), A disintegrin and metalloproteinase (ADAMs), Plasminogen 
activator inhibitor (PAI-1), and Cathepsins may answer questions relating to how ECM 
components are degraded. 
 Additional missing information in our study relates to the mechanism of WL, 
which may lead to multiple changes in metabolism/inflammation. HFD has been shown 
to be pro-inflammatory even with short term feeding, therefore, it is possible that the 
removal of the HFD stimulus independent of WL may be sufficient to alter inflammation 
and the ECM. Additionally, we cannot rule out that the intracellular collagen or elastin 
content we measured using flow cytometry is due to uptake rather than deposition. 
Further studies will be required to better understand the fate of the ECM components (i.e. 
fibril-formation and crosslinking) that are produced.  
 Our current model is that persistent fibrosis in adipose tissue is dependent upon 
the induction of a pro-fibrotic environment driven by diet-induced obesity. Here we 
propose a model, where the development of obesity induces both the expansion of 
preadipocytes, and also their expression of ECM components (Figure 4-7). With weight 
loss, we hypothesize that widespread lipolysis recruits and activates ATMs. Increases in 
the maturation and crosslinking of the ECM via crosslinking enzymes such as Lysyl 
Oxidase, increase the abundance of insoluble fibers, and degradation of ECM 
components lags, imprinting an imbalance of ECM deposition and degradation. Together, 
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this increase in fibrosis limits the physical flexibility of the ECM, perturbs adipocyte 
metabolism, and decreases insulin sensitivity.  
 Our study highlights a striking observation in the remodeling of the ECM 
architecture after WL. Even after this caloric restriction, insulin sensitivity was 
decreased, and we believe this finding is linked with our observation of increased fibrotic 
ECM accumulation after WL. The next viable question for the future is to understand 
how metabolic stress, such as lipolysis, influences gene expression of signals that 
promote the depot-specific persistence of PreAds. Studies point to PDGF signaling as a 
possible fate-determining mechanism which may direct this persistence (86, 163).  
Similarly, due to their unique microenvironment, exposure to inflammatory and 
growth factors, PreAd fate might be skewed toward a pro-fibrotic phenotype. 
Longitudinal studies that measure both ATM and PreAd populations are required to 
understand the dynamics of these population shifts, especially considering that short-term 
WL models in animals dramatically increase ATM populations, while human long-term 
weight loss models of reveal the opposite (29, 44, 106). The subject of future studies will 
be to resolve these variables and more closely analyze ATM-PreAd communications in a 
comprehensive collection of metabolic contexts and non-inflammatory conditions in 
order to understand their roles in influencing ECM architecture.  
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Figure 4-1. Fibrotic ECM composition is sustained after short-term weight 
loss. (A) Body weight, fasting glucose, fasting insulin, with (B) visceral epididymal 
(eWAT) and subcutaneous inguinal (iWAT) fat pad weights are shown for studies in this 
figure. (C) Trichrome collagen stain and Verhoeff’s Elastin stain on sectioned eWAT. 
Scale bar = 100uM.  n=3-4 per group. (*p<0.05, **<0.01***0.001, ****0.0001).  
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Figure 4-2. Insulin sensitivity decreases as ECM accumulation increases after long-
term weight-loss. (A) Body and tissue weights are shown after weight loss. (B) Glucose 
and insulin tolerance tests (GTT, ITT, respectively). (C) Picrosirius stains of eWAT and 
iWAT from ND (20wk ND) HFD (20wk HFD), and WL (12wk HFD, 8wk ND) animals. 
Scale bar = 100uM. (D) Total collagen content and collagen as a percent of total protein.  
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Figure 4-2 continued. (E). Density of endothelial and preadipocytes (PreAds) per gram 
of tissue and as a percent of stromal vascular fraction (SVF) at ND, HFD, and WL. n=4 
per group. (*p<0.05, **<0.01***0.001, ****0.0001). 
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Figure 4-3. Endothelial cells and preadipocytes are major collagen type I-expressing 
populations in the stromal vascular fraction.  Flow cytometry results, gated on CD45-
CD31-Sca1+ PDGFRα+ preadipocytes that express collagen I (ColI +) in eWAT (A) and 
iWAT (B).  ColI + endothelial cells and PreAds are shown as a percent of SVF (C,E) 
density of ColI + cells per gram (D, F) and median fluorescence intensity (MFI) (G, H) in 
eWAT and iWAT respectively. (*p<0.05, **<0.01***0.001, ****0.0001).  
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Figure 4-4. Endothelial cells and preadipocytes express elastin. (A) Elastin flow 
cytometry experimental controls. (B) Flow cytometry results, gated on CD45-CD31-Sca1+ 
PDGFRα+ preadipocytes that express elastin (Eln+) in eWAT and iWAT. (C, D) 
Measurements of Eln+ endothelial and PreAds as a percent of SVF and as density of Eln+ 
cells per gram of tissue. (E) Elastin staining intensity MFI in eWAT and iWAT. n=4 per 
group. (*p<0.05, **<0.01***0.001). 
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Figure 4-5. Gene expression of ECM components and remodeling factors after 
weight gain and weight loss. Gene expression of (A) ECM components, (B) markers of 
fibrosis, (C) remodeling enzymes, and (D) markers of browning. n=4 per group.  
(*p<0.05, **<0.01***0.001) 
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Figure 4-6. Secreted factors from weight loss tissues identify weight-dependent 
cytokine and growth factor changes. (A) Cytokine array membrane is shown, proteins 
increasing with obesity are highlighted in red boxes (IL-1RA and MCP-5) and proteins 
decreasing with obesity and increasing after WL in blue boxes (TNFα, MIP1α, 
RANTES). (B) Ratios of quantified pixel density from cytokine array, IL1-RA and 
MCP5 shown as blue and red arrows respectively. (C) ELISA analysis of TGFβ-1 in 
conditioned media from ND, HFD, and WL eWAT tissue explants. (D) Gene expression 
of fibrosis markers from 3T3-L1s treated with TGFβin. n=4 per group. (*p<0.05, 
**<0.01***0.001, ****0.0001).  
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Figure 4-7. Model of ECM accumulation after weight loss. The progression from the 
lean to the obese states results in new adipogenesis, adipocyte hypertrophy, and the 
activation of extracellular matrix (ECM) production in preadipocytes. In the obese state, 
Adipose tissue macrophages (ATMs) secrete factors that activate ECM production and 
proliferation by preadipocytes. With weight loss, adipocytes shrink in size via lipolysis, 
which recruits and activates additional ATMs and stimulates expansion of preadipocyte 
populations.  ECM forms insoluble fibers that are created by crosslinking enzymes. A 
decrease in the relative ECM degradation results in an imbalance, which favors the 
permanence of ECM components. Additionally, mechanical stress imposed by a fibrotic 
ECM limits adipocyte energy regulation and decreases insulin sensitivity. 
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Chapter 5 
 
Conclusions, Limitations, Future directions, and Clinical Relevance  
 
Conclusions 
Adipose tissue functions as the main nutrient storage organ, which is capable of 
rapid adaptation to metabolic demand. In settings of over nutrition, adipocyte 
hypertrophy and new adipocyte formation serve to increase fat mass. With negative 
energy balance adipocytes releasing its stored nutrients in the form of triglycerides to 
meet metabolic demand and adipocytes decrease in size. Disturbances in the efficiency of 
these remodeling events can disrupt the normal homeostatic function of adipose tissue 
and over time can contribute to systemic insulin resistance. In this scenario, with adipose 
tissue dysfunction, the energy stores that were once managed efficiently by adipose tissue 
are not well contained, resulting in ectopic energy storage in tissues such as liver and 
muscle (202, 203).  
While there are many potential contributors to the metabolic disease with obesity, 
these projects have focused on ECM deposition and fibrosis as a mediator of adipocyte 
dysfunction. The adipose tissue ECM normally functions to physically support the 
structure of the tissue and provide the mechanical and cell adhesion cues that influence 
cell fate. The ECM provides required cues which are needed to drive adipocyte growth 
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and differentiation, however, excessive ECM accumulation negatively influences 
development and metabolism (165). In vitro studies show that growing adipocytes in 
dense fibrous material-laden ECM results in an increased inflammatory response and 
inhibition of differentiation (154, 173).  
 ECM remodeling, as we have described as the balance between the deposition and 
degradation of the ECM along with post-translational modifications, is important to 
support normal adipose tissue expansion. The composition of the matrix itself has the 
potential to influence adipocyte function and can influence whole-body metabolism upon 
high fat diet challenge. Studies have shown that reducing the capacity of an adipocyte to 
degrade its pericellular ECM via a lack of functional matrix metalloproteinase (MMP) 
inhibits adipocyte hypertrophy (41, 42). A lack of MMP inhibitors can on the other hand, 
increase adipose tissue expansion (87). Similar findings were shown in animal models 
lacking a particular ECM component, Collagen VI, in which animals gained excessive 
weight, had more hypertrophic adipocytes, but were still metabolically healthier (97).  
While there is a vast amount of literature reporting the negative effects of 
inflammation and adipose tissue fibrosis in the pre-clinical rodent models, inflammatory 
pathways are also required in adipocytes for normal metabolic homeostasis (232). 
Therefore, a careful balance on the level of inflammation is required in the adipocyte 
microenvironment for normal physiological expansion and ECM remodeling.  
 
Key findings in the degradation of the adipose tissue extracellular matrix 
 In this work, we approached the ECM degradation/deposition paradigm in the 
context of adipose tissue fibrosis with three different models. In our first approach, we 
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hypothesized that the depletion of one key elastin-degrading enzyme, MMP-12, would 
increase the accumulation of ECM components, namely elastin, and result with metabolic 
perturbations during the development of obesity. We identified an elastin matrix forming 
a mesh-like network around all adipocytes. We also determined that that MMP-12 in 
adipose tissue is primarily produced by ATMs, however in whole-body MMP-12 
deficient animals, we observed no observable difference in elastin matrix architecture or 
in metabolism. Our data suggests that MMP-12 does not play a major role in influencing 
ECM remodeling or whole body metabolism. Other elastin-degrading enzymes exist, 
however very little is known regarding their specific role in reorganizing the Elastin 
matrix in adipose tissues.  It is also possible that elastin inhibitors such as α1-antitrypsin 
play a prominent role in elastin regulation (229). Neutrophil elastase (NE) has been 
shown to promote adipose tissue inflammation and promote insulin resistance with DIO 
(205). Mice deficient of NE are resistant to diet-induced obesity, insulin resistance, 
inflammation, and fatty liver (130). Additionally, mice deficient of NE do not develop 
diet-induced obesity-mediated adipose tissue fibrosis. Taking together, we speculate that 
elastin degradation subunits may promote inflammation and metabolic dysfunction.  
However, it is still unclear if NE has roles specific to elastin ECM degradation in adipose 
tissue, or if its roles are limited to mediating inflammation. Another elastin degrading 
enzyme Matrix metalloproteinase-7, (MMP-7) or matrilysin has also been implicated in 
obesity and weight loss. Formally obese patients increase circulating levels of MMP-7 
post bariatric surgery, which may indicate an induction of remodeling or degradative 
activity of ECM architecture with weight loss (180). An alternative explanation to this 
may be that MMP-7 may be facilitating the activation of other interrelated MMPs, 
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thereby activating a cascade of ECM remodeling. Further studies investigating adipose 
tissue specific NE or MMP-7 activities may elucidate mechanisms relating both to Elastin 
matrix architecture remodeling and inflammation.  
 
Preadipocytes produce key extracellular matrix components related to fibrosis 
In Chapter 3, we set out to understand the mechanisms of the deposition of a key 
insoluble ECM component, fibrillar collagen type I. Our results implicate preadipocytes 
as the primary regulated source of collagen type I production induced with DIO primarily 
in the gonadal fat pads and not subcutaneous fat pads.  Microarray analysis and 
intracellular protein detection corroborated these findings.  Several studies have 
suggested that preadipocytes take on a pro-fibrotic phenotype in obesity triggered by 
macrophage inflammatory cues, but no studies have provided convincing evidence that 
these cells produce ECM proteins in vivo (25, 96).  
ATMs and preadipocytes co-localize in ECM-dense regions in crown-like 
structures.  While some studies have examined the influence of classically activated (M1) 
macrophages on preadipocyte function, the influence of the full range of macrophage 
activation states on preadipocyte ECM production are unknown (24, 25, 198). 
Considering that ATMs were a major source of TGFβ-1, we hypothesized that 
macrophage activation states played a major role in the regulation of type I collagen 
expression. In vitro experiments revealed that alternatively activated resident “M2” 
macrophages, not classically activated “M1” or metabolically activated macrophages 
“MMe” induced expression of fibrillar type I collagen. Using a small molecule inhibitor, 
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we determined that TGFβ-1 signaling was required for resident macrophages to produce 
the pro-fibrotic effect in primary preadipocytes.  
Our data suggests that preadipocytes are the main source of fibrillar type I 
collagen expression, and that preadipocyte-macrophage communications leading to pro-
fibrotic activations are TGFβ-dependent. This is in agreement with findings in other 
fibrotic diseases as scleroderma animal models have also implicated TGFβ signaling in 
the pathogenesis of this form of subcutaneous adipose tissue fibrosis (162).  Further, both 
a systemic blockade and a genetic depletion of TGFβ-dependent Smad3 signaling 
attenuated the development of fibrosis and prevented glucose intolerance (236). These 
findings further suggest that TGFβ signaling is required for tissue homeostasis and may 
be a potential target to treat obesity and diabetes by attenuation of adipose tissue fibrosis.  
Several important questions remain. While we are able to measure increases in 
collagen type I expression, it is still unclear if preadipocyte derived collagen type I is 
required for the development of adipose tissue fibrosis given the wide range of other 
collagens that are produced in adipose tissue and induced at the gene expression level 
with obesity (74). Additionally, we have not investigated the production or the role other 
non-collagen ECM components, which may also have the potential to influence adipocyte 
maintenance, turnover, and tissue inflammation, as was shown by Khan et al (97). There 
is also the potential that accumulations of only certain types of collagens, fibrillar or even 
non-fibrillar, may lead to local inflammation and metabolic dysfunction. We made 
attempts at proving the importance of preadipocyte Collagen type I experimentally in 
mice by using cre-lox technology. To generate an inducible deletion of Col1a1 gene in 
preadipocytes we crossed Pdgrfa-creERT transgenic mice with a floxed Col1a1 
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transgenic mouse (93). We were unable to show efficient excision of the transgene after 
inducing recombination with tamoxifen.  This model suffered several technical 
limitations that included mosaic expression of the transgene and leaky Cre expression in 
the absence of tamoxifen induction.  This is a general weakness in the field as no 
currently available transgenic models are able to specifically modify gene expression 
uniformly in preadipocytes (16, 88). 
 
Weight loss induces a dynamic increase in adipose tissue fibrosis 
In Chapter 4, we set out to understand the dynamics of ECM reorganization with 
weight loss. Human studies suggest that adipose tissue fibrosis appears to persist and may 
even increase after weight loss (53, 54, 135). In contrast, exercise may attenuate the 
development of diet-induced adipose tissue fibrosis (95). Therefore, we set out to 
understand the pathogenesis of weight loss induced adipose tissue fibrosis in animal 
models.  We observed a significant increase in collagen accumulation in visceral fat and 
lower insulin sensitivity in animals that underwent weight loss compared to weight 
matched lean mice. While there were more preadipocytes in weight loss mice, the per cell 
expression of intracellular collagen and elastin was decreased compared to obese mice.  
This suggests that ongoing ECM deposition may not the primary mechanisms behind the 
increase in ECM accumulation with weight loss, but that there may be a long-term 
persistence in the inability to degrade adipose tissue collagen once it is deposited and 
cross-linked with diet-induced obesity.  
 These findings reinforce the multi-faceted nature of the regulation of the adipose 
tissue ECM and that our focus on collagen production alone may not be sufficient to get a 
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full picture of how ECM is remodeled.  ECM remodeling requires tight regulation of 
elements that produce, organize, deposit, and degrade ECM components. Our 
investigations into the sources of fibrillar ECM components reveal that preadipocytes are 
major sources of type I collagen and elastin, which supports previous studies into pro-
fibrotic preadipocytes (96).  Currently we are limited by the availability of assays to 
reliably measure ECM degradation in and around adipocytes in the context of adipocyte 
hypertrophy or regression.  This is an overall weakness in the field that we have made 
attempts to address.  Unpublished experiments we performed examined changes in 
collagenase activity zymography with variable results potentially due to the harsh 
conditions required to remove lipids from adipose tissue prior to analysis.  Cellular assay 
of ECM degradation of fluorescence collagen matrices identified macrophage-dependent 
collagen degradation, however this was not quantitative. Most studies published to date 
depend solely on gene expression analysis for assessment of collagen degradation or 
deposition, but the significant post-translational modification of the ECM make such 
measure unreliable in our experience to date.   
Such more advanced measures are required to get a better understanding of the 
longitudinal changes that regulate adipose tissue ECM accumulation with weight loss.  
Currently, it is not clear at which point the density of the ECM increases and how to 
differentiate this from a stable ECM network that condenses as adipocytes shrink in size. 
We feel that our studies are consistent with the model that weight loss might trigger ECM 
degradation at a slow rate that does not overcome the large amount of ECM that has been 
deposited with initial weight gain.  Published data on ECM status after weight loss in 
animals is limited, therefore additional studies investigating ECM architecture at the gene 
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expression level, biochemical level, and histological level are in need. A potential 
alternative approach for future studies include the use of de-cellularized adipose tissue to 
study and quantify ECM structure and protein content (28, 164).   
 
Limitations 
 
 Our animal models and experimental techniques have several limitations of which 
we are aware. One major limitation is the use of diet-induced obesity models that employ 
a high fat diet chow composed of 60% calories from animal lard. While high fat 
consumption is one potential contributor to human obesity, there is evidence that 
carbohydrate excess is more relevant to metabolic disease than fat excess (46, 212).  We 
might have observed difference effects on adipose tissue ECM composition, preadipocyte 
expansion, and macrophage accumulation if high carbohydrate diets were employed.     
Another limitation, which is not well documented in the field but is 
acknowledged, is the large regional variability of ECM accumulation between and within 
tissues in animals. For example in the gonadal fat pads we have primarily focused on, 
fibrosis and ATM accumulation are highly concentrated in the rostral “tip” of the fat pad 
and decrease in the caudal “base”.  This may relate to blood flow at the tip region, which 
may be limited compared to the base.  Another significant challenge in our experiments 
and in the field is normalization of stromal cell and other measures in tissues that are 
changing 100-300% with dietary manipulation.  For example, histology in obese mice 
with very large adipocytes may underestimate the amount collagen in adipose tissue and 
may not correctly represent the true quantity and structure of the ECM with obesity.  
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In addition, normalization for biochemical assays, such as hydroxyproline and 
total protein content assays, have weaknesses due to the increase in lipid content per mg 
of total tissue input. We have observed that normalizing to total protein, or tissue weight 
may not be feasible methods of comparing ECM content in adipose tissues. We postulate 
that total DNA content may similarly not be feasible for ECM content comparisons 
because the cellularity and stromal cell content increases in adipose tissues from obese 
animals. As previously mentioned, fibrosis development is not homogenous in nature; 
therefore alternative approaches to measuring total collagen accumulation need to be 
considered for future studies. Such possible strategies may include the de-cellularization 
of an entire eWAT fat pad, followed by normalization of total protein content per input 
mg, and by hydroxyproline total collagen content. This method may remove the risk of 
regional variability of ECM content, yet may still adequately represent the total collagen 
content per unit of total protein.   
 The majority of our studies focus on the epididymal peri-gonadal fat pads 
(eWAT) in mice, which has been shown to be the most pro-inflammatory and fibrotic in 
many studies.  Such a depot is not prominent in humans and there is a valid concern in 
the field that eWAT may not represent a true visceral adipose tissue depot. Still, in 
animal studies, the eWAT is highly responsive to metabolic stress, inflammation, and has 
been studied extensively for its ECM content. We note that the issue of which visceral fat 
depot is the most deleterious in humans remains an open question, as omentectomy has 
not proven to have significant effects on improving metabolic control (51, 120).    
 Our methods for studying intracellular collagen content via flow cytometry also 
come with caveats. At this time, we are unable to completely exclude the possibility that 
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the intracellular collagen or elastin we are detecting is taken up from the environment. In 
the pulmonary fibrosis literature, ColI+ fibrocytes were recently definitively proven to 
derive from injected collagen type I and not from endogenous production (175). While 
our controls and gene expression data argue that under static conditions, Collagen I 
positivity is a measure of intracellular production, there may be other circumstances 
where a combination of production and uptake contribute to this signal.  We have made 
attempts to use pro-collagen antibodies to support this finding but these were not 
technically feasible with the reagents currently available.  Future use of antibodies that 
detect degraded collagens type I may be useful measure. Along the same lines, a 
weakness of our studies is that we are currently unable to investigate the eventual fate of 
the ECM components after production by the preadipocytes. Steps between production 
and deposition include protein folding, post-translational modification, and crosslinking, 
which we are currently unable to measure in vivo. Alternative strategies using GFP-
labeled collagen or elastin may prove useful to assess these events.   
 In our studies investigating mechanisms of the pathogenesis of adipose tissue 
fibrosis, we identified TGF β -1 as a likely mediator of ATM-preadipocyte 
communication. Our studies however, did not investigate the activation state of TGFβ-1 
when performing conditioned media experiments. As previously mentioned, TGFβ-1 is 
expressed in multiple latent forms, and further activation by proteolytic cleavage by other 
ECM processing enzymes such as matrix metalloproteins is required for signaling to 
occur. Future investigations of activation states may be performed with currently 
available antibodies designed to detect TGF in its active and latent forms.  
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Future directions 
 
While the understandings of the physiology of adipose tissues have increased 
dramatically over the last decade, there is still much that is not understood. There are 
several outstanding questions that extend from the work presented in this dissertation. 
 
How is the adipose tissue ECM degradation machinery regulated?  
Most published studies, including our own, focus mostly on markers and elements 
of ECM composition, however few have studied the ECM degradation machinery and its 
regulation by weight gain and loss. Plausible future studies include the use of transgenic 
models deficient of multiple but related degradation enzymes to understand both the roles 
of the enzymes, and also their own internal specific ECM substrate. 
 
What role do growth factors play in adipose tissue physiology? 
 We, and others, have implicated macrophage-derived TGFβ-1 signaling as being 
required for the induction of primary preadipocytes toward a pro-fibrotic phenotype. 
Additional studies investigating the prevalence of TGFβ-1 in its active form in adipose 
tissues as well as its form when secreted from whole explants will be necessary to 
understand the degree to which this mode of signaling is active. In addition, groups have 
also implicated PDGFRα+ cells and PDGF signaling in adipose tissue specifically, in the 
initiation of fate-determining and fibrogenic mechanisms (86). Investigations into these 
two growth factors and signaling mechanisms may shed light into the physiology and 
metabolic regulation of adipose tissues.  
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What is the fate of newly synthesized ECM and what is the importance of crosslinking? 
 While we were able to detect increases in staining of intracellular ECM 
components such as collagen type I and elastin, we were unable to determine their final 
form or destination. Future studies will be required to understand if those components 
end up in insoluble fibrillar form, or if they are degraded. Additionally, investigating the 
role of crosslinking enzymes such as Lysyl Oxidase, the Lysyl Oxidase Like family of 
enzymes (LOXL1-4), and Transglutaminases (TGM2) would provide key information 
regarding the maturation and formation kinetics of insoluble ECM fibers (2). This could 
be performed using available small molecule LOX inhibitors. Additionally, there is 
evidence that of TGFβ-mediated LOX induction, which indicates that TGFβ may have 
roles in ECM production as well as ECM cross-linking (189).   
 
What measures best define adipose tissue fibrosis?  
 Currently there is no strict definition of criteria that defines ECM tissue as 
fibrotic. In the future, more comprehensive quantitative methods will be required in order 
to convincingly compare studies. Possible approaches include de-cellularizing the entire 
fat pad, normalizing total hydroxyproline content to total DNA, or to an average total cell 
density, which would require knowledge of number of adipocytes and adipocyte size. 
Ideally, future studies can better quantify fibrotic accumulations by measuring amounts 
of insoluble ECM materials collected after tissue dissociations.   
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What is the role of obesity-induced inflammation in ECM deposition and degradation? 
 Our cytokine array studies suggest that inflammatory cytokines may not be direct 
inducers of fibrosis in preadipocytes. However there is still much left to investigate 
considering the prevalence of ATMs and their varying activation states with obesity and 
weight loss.  ATMs are recruited to CLSs, which are also prevalent fibrotic areas, which 
indicates that inflammation may be an initial step in the activation of a pro-fibrotic ECM 
architecture reorganization (114, 115). Investigating the role of obesity-induced 
inflammatory cytokines in activating phenotypes in ATMs is necessary, and can be done 
with animal models deficient of activation receptors (TLR 4 deficient, CD11c deficient, 
IL4 deficient) or those deficient of inflammation of all together (RAG knockout, NOD).  
 
Clinical Consequences of adipose tissue fibrosis 
 
Is fibrosis bad, or good?  
 While the majority of pre-clinical studies support the model that adipose tissue 
fibrosis is pathogenic, there is evidence that it may also be metabolically protective in 
humans. Visceral adipose tissue fibrosis may impart protective effects on metabolic 
disease by limiting adipocyte hypertrophy and promoting the formation of smaller 
adipocytes, which are associated with less inflammation (9, 10). Patients with larger 
adipocytes have a more disrupted metabolic profile (9). Studies show that patients with 
smaller adipocyte sizes, due to fibrotic accumulations that restrict adipocyte hypertrophy, 
have improved blood plasma lipid profiles (203). In fibrotic visceral adipose tissues, 
lower levels of circulating triglycerides were found; consequently it is not out of the 
123	  	   	  
question that fibrosis may impart protective effects to some degree (203). In contrast, 
fibrosis in subcutaneous adipose tissue depots may have the opposite effect and lead to 
preferential accumulation of nutrient stores and adipocyte hypertrophy in visceral fat 
depots.  Therefore, we speculate that adipose tissue ECM may be a regulator of body fat 
distribution between visceral and subcutaneous depots. Support for this hypothesis comes 
from GWAS studies demonstrating association between many genes that control 
mesenchymal cell function, angiogenesis, and adipogenesis and body fat distribution (59, 
193, 194).  
While adipose tissue fibrosis shows fairly uniform responses in mouse models of 
obesity, there are a variety of reasons why clinical studies still lack substantive evidence 
in either direction of adipose tissue fibrosis pathogenesis. Current studies vary in the 
sense that some studies only measure fibrosis in one adipose tissue depot, only study 
gene expression, or are solely based on correlative studies (73,143,192). Studies 
investigating causative effects of fibrosis in adipose tissue, that include in depth 
examinations of metabolism do not currently exist, this remains a noteworthy barrier to 
research in this field. Overall, the association between adipose tissue fibrosis, 
inflammation, and metabolic dysfunction is not clearly delineated in human studies. 
 
Reversibility of fibrosis 
Currently, there is little evidence that fibrosis is reversible. Studies have 
investigated the results of weight loss on fibrosis that occurs in the liver, however results 
are mixed. Studies of weight loss using bariatric surgeries also remain controversial, as 
some patients are poor responders to surgery (1). Some studies however, describe a 
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decrease in expression of ECM components after weight loss surgeries (55, 101). A study 
of gene expression and histology of adipose tissues of the same patients before and two 
years after surgery report no decreases in fibrosis (29).   
 
Concluding remarks 
In closing, fibrosis is regarded as a hallmark of dysfunctional adipose tissue. At 
the start of our studies the primary source of ECM production in obesity and the 
mechanisms that drive it were unknown. Our studies contribute to the field by implicating 
ATM-preadipocyte communication as a potential modifiable node in the link between 
obesity and adipose tissue ECM deposition that may be targeted to improve metabolic 
health.  Further studies are required to better relate our findings clinical settings to better 
understand associations between fibrosis, adipose tissue stiffness, and metabolism.  
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